

SUBJECT INDEX 1962

This index covers all reading matter in Volume 11 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. Those preceded by the letter "S" refer to the Volume 11 Supplement entitled *Tolbutamide Therapy after Five Years*. The Author Index appears on page 17.

A

ACD. Acid-Citrate-Dextrose, 261

ACETATE

enzymatic method determination, *76
ketone bodies, conversion to, *157
salicylate administration effect, *77

ACETOACETATE, oxidation, *353

ACETOHEXAMIDE

and blood sugar, *348
efficacy and toxicology, 83-90, *551
and hypoglycemia, *552

ACID. *See* specific acid

ACIDOSIS, DIABETIC

See also Ketoacidosis
and beta-hydroxybutyric acid, 25-29
and exudative cellular response, *551
and fetal loss, *346
and insulin
dosages, 23-28
resistance, 30
management, *75
metabolism, 363, 369
mortality, 25
and nitrogen deficiency, *154

ACTH. *See* Adrenocorticotropic hormone

ADDISON'S DISEASE

insulin requirement, *548
and sulfonylureas, *78

ADRENAL GLANDS

cortex
atrophy, 212
and Cushing's syndrome, *158
and diabetic lesions, 410-411
enlargement, 17-18, 319
after pituitary surgery, 471
and hyperglycemic action of glucagon, *158
medulla
hypofunction in childhood hypoglycemia, 421

ADRENALECTOMY

and blood sugar levels, *78
and epinephrine, *159
and glucagon
metabolism, *248
reaction in baboons, *158

and insulin

antagonists, *352
response in muscle, 175
sensitivity, *343-344
and retinitis, 483-485
and retinopathy, 461-462, 485-490,
491-494

ADRENALIN. *See* Epinephrine

ADRENOCORTICOTROPHIC HORMONE

and free fatty acid release, *343, *352
histological effects, 402-410
and 17-hydroxysteroid excretion, 487
hypophosphatemia, effect on, 31
and insulin resistance, 31-34
lipolysis, *246
and phosphorylation, 31
after pituitary surgery, 471
and retinal microaneurysms, 18

AGE FACTOR

in basement membrane thickening, 9
in blood sugar levels, *78
in chlorpropamide therapy, 92-94, S99-100
in diabetes
mortality, 66
onset, 46-47, 61-63
and sera proteins, 331
in glucose tolerance, *154
growth trends in teens, 52, 55
in Increment Index, S128-129
in pregnant diabetics and tolbutamide, S100
and working capacity, 111

AH6848. *See* Methoxypropyl-sulfonilylurea

ALBUMIN

free fatty acids removal, *352
glycocorticoid effects, 105
and insulin
antagonist, *351, *352
resistance, *76
and sulfonylureas, bound, S19-24

ALLOXAN. *See* Diabetes mellitus, alloxan-induced

9 ALPHA-FLUORO-11 BETA-HYDROXY-17-ALPHA-METHYL-TESTOSTERONE, and glycogen storage disease, *547

9-ALPHA-FLUOROHYDROCORTISONE

and adrenalectomy, 486
histological effects, 402-410

AMERICAN DIABETES ASSOCIATION

Affiliate Associations, 81-82, 163, 259-260, 357, 456, 558
Detection Drives, 81

annual meetings

Twenty-first

Bylaws amended, 81
new procedure for submission of abstracts, 79

Twenty-second, 79, 161, 252-253, 445-450

Annual Session of Delegates, 447
The Banting Medal, 445

business meeting, 447-450

elections, 354

Executive Director's report, 448-449

memorial tributes, 445

Nominating Committee report, 450
registration figures, 354

scientific sessions, 253

special sessions, 447

Treasurer's report, 448

Twenty-third, 258

submission of abstracts, 454, 554-555

Banting Memorial Lecture, 361-370

Board of State Governors, 555-556

Committees (1962-63), 556-557

contests

essay, 80, 453-454, 555

research, 555

Diabetes Week, 80, 162, 258, 356, 455

FORECAST

Diabetes and Urinary Tract Infection, 455

Emergency Medical Care for Diabetics, 557

Endocrine gland series

The Adrenals, 162

The Pituitary, 356

The Thyroid, 80

Summer Camps for Diabetic Children, 162

Urine Testing—Its Methods and Its Importance, 258

Friedenwald Award, 82

International Diabetes Federation

Fifth Congress, 258, 356

Fourth Congress, 138-143, 228-235

proceedings, 457

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

Volume 11 Supplement, 1-150

September-October, 361-460

November-December, 461-562

SUBJECT INDEX 1962

JOURNAL

Editorials

The Case for the Routine Use of Diets High in Polyunsaturated Fat for Diabetics, 340-341

Diabetes Mellitus: Still an Inadequately Recorded Disease, 239-240

Diabetes, Overweight, and Elevated Blood Pressure, 544-545

Fact and Fancy Concerning Tracer-Determined Flux and Accumulation of Substances in Vivo, 236-239

Insulin and Protein Synthesis in Isolated Tissues, 144-146

Nicotinic Acid and Diabetes, 144

Problem of Insulin in Blood, 69-70

Steatorrhea in Diabetic Patients, 436-437

Index, 557

new procedure for abstract submission, 79

special subscription rates, 80

Lilly award, 162, 356, 454-455

In memoriam

Jolliffe, Norman, 147-149

Joslin, Elliott Proctor, 242-244

Muhlbarg, William, 340-341

Reed, John Alton, 438-439

necrology, 82, 260, 357, 457, 558

new members, 81, 162, 258-259, 357, 455-456, 557-558

News Notes, 82, 163-164, 260, 357, 457, 558

personals, 260, 357, 457, 558

postgraduate programs, 81-82, 164, 257, 356, 451-453, 554, 558

publications

binders available, 80

Membership Directory, 81

"Treatment of Diabetes," 117

research fellowships, 258, 356, 455

Research Symposium, first, 554

program, 355

scientific programs, 79, 253

exhibits, 258

list of papers, 254-257

AMINO ACIDS

and hypoglycemia after leucine, *250

and insulin, *342, *348, *442, *546

beef-pork, 125

metabolism, *159, 544

myocardial, *152

protein, incorporation in, 145, *249

AMPUTATIONS, below-the-knee, *346

ANEMIA, incidence, *344

ANEURYSMS. *See* Microaneurysms

ANOREXIA, long-term therapy, *74

ANOXIA

and galactose uptake, *550

and glycolysis, *76

ANTIBODIES

insulin, *151, 308, *440

animal and human, 124-125, 416-418, 519-526

in childhood diabetes, 122-124

circulating, *348

and heat labile factor in gamma globulin, 188

and insulin resistance, *347

in plasma, 527-532

properties, 519-526

and steroid therapy, 168, *343

and tolbutamide effects, S29-30

APPETITE, regulation, *444

ARGENTINA, Congress on Nutrition, 260

ARTERIOSCLEROSIS

of choroid, 17

in Hiroshima survey, 538

nondiabetic

and retinal vascular disease, 11

ATHEROSCLEROSIS

and beta-glucuronidase activity, 65

and cholesterol, 144

and diet, 65, *77, 221

and glucose tolerance, *352

and insulin, *77

and retinal vascular reactivity, *74, 526

ATOMIC BOMB CASUALTY COMMISSION IN HIROSHIMA, (ABCC)

Adult Health Study, 533-534

AZEPINAMIDE, 218-219

comparison with

chlorpropamide, S143

tolbutamide, S143

and hypercholesterolemia, S70-71

and hyperlipidemia, S70-71

toxicity, S144-145

B

BANTING AND BEST COMMEMORATIVE MEDAL, 374

BANTING MEMORIAL LECTURE, 361-370

BANTU

diabetes and hemochromatosis, *251

pregnancy, diabetic

and chlorpropamide therapy, S99-100

and tolbutamide therapy, S99-100

BASEMENT MEMBRANE

thickening

of Bowman's capsule, 293, 305

and insulin-anti-insulin complex, 314

and lumen occlusion, 293

BELFAST, ROYAL VICTORIA HOSPITAL DIABETES CLINIC, 91

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

Volume II Supplement, 1-150

BENEDICT'S COPPER REDUCTION

TEST, 53-55

BLINDNESS. *See* Retinopathy

BLOOD

See also Blood sugar, Plasma, Serum acetaldehyde level, 40-42

acetate, *76

ammonia level and fetal loss, *346

and beta-hydroxybutyric acid, 25-29

cholesterol and work tests, 114

cortisol, 487

free fatty acids, 223

galactose concentration, *155

and galactosemia detection, *159-160

insulin

activity, *245

assays, 69-70

free and complex, 261-266, S34

-like activity, S46

and pancreatoduodenectomy, *247

ketone bodies, 26, *157

Bessman and Anderson method, 24

lactate level, 285

lipids, *74

azepinamide effect, S71

after exercise, 113

tolbutamide effect, S70

and liver glycogen disease, *550, *553

oleic acid, *549

peripheral and insulin, 506

phosphate

and metabolism, intracellular, 29

plasma

and glucose, *549

and tracer methods, 236-238

pyruvate level, 285, *548

tests

in healthy old people, *154

Kent-Jones and Taylor method, 40

screening, 44-45, *160

Stotz's method, 40

tolbutamide levels, S94

triglycerides

and work tests, 114

urea, 484, 485

nitrogen, 24

BLOOD FLOW. *See* Circulation

BLOOD GLUCOSE. *See* Blood sugar

BLOOD GROUPS, and disease associations, 329

BLOOD PRESSURE

See also Hypertension

and adrenalectomy, 488

and bacteremic shock, *347

in diabetic retinopathy, 11-12

after gastrectomy, *152

and hyperglycemia, *348

and hypophysectomy, 462, 471, 477

increase and glomerulosclerosis, *440

and insulin, *348, 396, 421

BLOOD SUGAR

abnormalities, *440

after acetohexamide therapy, 87

SUBJECT INDEX 1962

after adrenal steroids administration, 32
 adrenalectomy effect, *78
 and antibiotic drugs, *345
 and anti-insulin serum, S26-33
 and 2, 2'-bipyridine, *442
 and chlorothiazide, *441
 after chlorpropamide therapy, 92
 and cortisone, 211
 in "diabetic" index, *442-443
 after exercise, 111-112, 114
 fasting, 45, *78, *154
 in controlled diabetics, S58
 after insulin, S44-45
 after tolbutamide, S44-45
 after glucagon, *73
 after growth hormone administration, 427
 hydrocortisone effect, 174
 in infants
 of diabetic mothers, *153
 and tolbutamide, S95-96
 and insulin
 antibodies, 520-522
 dosages, 23-28
 free, increase of, S34
 and leucine, 399, *552
 and liver
 glucose activity, *73, 270
 glycogen disease, *550
 maternal and fetal, 324
 in pancreatic vein, 505
 and phenethylbiguanide, *348, *551
 and phenformin, *160, 284-285
 and severity of diabetes, 45
 and sulfonylureas, *348, S61-68
 tests
 comparison of methods, *158
 comparison of test results, 204-208, *351
 Dextrotest method, *158
 Folin-Malmros, S104, 534
 Folin-Wu, 204-208
 glucose oxidase method, 53
 after goldthioglucose administration, 210
 Hagedorn-Jensen, 31, 44, 202, 210, S138
 sequential, *245
 Somogyi-Nelson method, 24, 49-50, 53, 87, *154, *158, 204-208, 428, S37, S94, S116, S135
 and thiohexamide, *348, *552
 and tolbutamide, *352, S2, S70, S124-125
 test, S97-98
 in infants and children, S135-136
 and wound healing, *250

BLOOD VESSELS

See also specific sites
 alterations in diabetes, *441
 aorta
 insulin effect, 422-425
 arterial
 atheromatous occlusion, *553
 arterioles
 hyalization, 9-11, *440

capillary
 microaneurysms, 4-8
 in tissue, adipose, 383
 and venous blood sugar, *154
 capillovenous
 glucose differences, *444
 coronary artery disease, *252, 485
 in eyes
 hypophysectomy effect, 476-477
 and glomerulosclerosis, 297-304
 peripheral disease, 538
 retinal
 nervous element support, 14
 and oxygen inhalation, *74
 and retinopathy, *252

BONE
 marrow aplasia, *353
 necrosis in feet, *76

BOOK REVIEWS

Annual Review of Biochemistry, edited by J. M. Luck, 240-241
 Cardiacs and Diabetics in Industry. A Study in Work Experience, by Grace Wyshak, Leonid S. Snegireff, and Augusta F. Law, 240
 Clinical Research in Diabetes and Pregnancy, edited by Jorgen Pedersen, 545-546
 Comparative Physiology of Carbohydrate Metabolism in Heterothermic Animals, edited by A. W. Martin, 437
 Contribution à la Biochimie des Obésités Experiméntales, by J. Christophe, 241
 Diabetes in an English Community, by Joan B. Walker, 241
 Diet Manual, compiled by Dietary Staff of Vanderbilt Hospital, 341
 Disease and Injury, edited by Leopold Brahdy, 149
 The Human Adrenal Gland, by Louis J. Soffer, Ralph S. Dorfman, and Jacques L. Gabrilove, 437
 Oral Treatment of Diabetes (A Clinical and Experimental Review), by Werner Creutzfeldt and Hans-Dieter Söling, 149
 The Pancreas in Human and Experimental Diabetes, by Sydney S. Lazarus and Bruno W. Volk, 546

BOSTON CITY HOSPITAL OUT-PATIENT CLINIC, 204

BRAIN

blood vessels
 and yttrium implants, 482
 capillaries, dilated in diabetics, 9
 glioma, 127
 glucose and oxygen difference, *444
 glucose permeability, 209

hypoglycemic effects, *72-73
 hypophysectomy effect, 462
 medulloblastoma
 and neovascularization, 130
 trypsin digestion preparation, 126-128
 mucormycosis, *155, *342
 nerve palsies, *348
 salicylates administration effect, *77

BRATTON AND MARSHALL PROCEDURE, S19

BRITISH DIABETIC ASSOCIATION
 chlorpropamide and placebo study, S129
 papers presented at meeting, 131, 160, 201, 290

BRÜCH'S MEMBRANE, 17

BUILD AND BLOOD PRESSURE STUDY, 52, 55, 196, 544-545

C

CAMP NYDA
 medical problems, *74, *249

CANCER
 and insulin resistance, *348
 pancreatic, 120, *246
 tolbutamide test, *439

CAPE TOWN SERIES

pregnancy, diabetic
 and chlorpropamide therapy, S99-100
 and tolbutamide therapy, S99-100

CAPILLARIES. *See* Blood vessels

CARBOHYDRATES

in diet, diabetic, *350
 and insulin deficiency, *159
 and liver lipids, *250
 metabolism, *548
 and anabolic steroid, *549
 in beta cells, 99
 in healthy old people, *154
 in liver, 364-365
 in newborn infants, *153
 in pregnant nondiabetics, *158
 thiazide drugs, effect of, *251
 tolerance, 44-45, *72
 and chlorpropamide, S127-129
 and hyperadrenocorticism, 171
 after nicotinic acid, 144
 after sulfonylureas, *252
 and tolbutamide, S123-126
 utilization
 after sulfonylureas, S66
 in young diabetics, S125-126

CARBON DIOXIDE

in carbohydrate metabolism, 369
 glycogen synthesis effect, 367-369
 ketone bodies, *157
 production, *249

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360

Volume II Supplement, 1-150

September-October, 361-460
 November-December, 461-562

SUBJECT INDEX 1962

CARBUTAMIDE
 alpha globulin bound, S19-22
 Bratton and Marshall procedure analysis, S19
 dose-response, 84
 and hepatic glucose release, S16-17
 and islet weight, S117
 teratogenic action in rats, S98
 thrombocytopenic effect, *346
 toxicity, 94, 216

CARNITINE, and fatty acid oxidation, *160, *248

CASE REPORT
 Addison's disease, *548
 azotemia, *246
 cerebral mucormycosis, *342
 cretinism and diabetes mellitus, *248
 diabetes in identical twins, 393-395
 emphysema, subcutaneous, *343
 estriol excretion, 515-516
 estrogen therapy in retinopathy, *250
 gastric atony, *353
 hyperlipemia, S69
 and hypercholesterolemia, S69-70
 idiopathic, *344
 and retroperitoneal fibrosarcoma, *350
 insulin
 antagonism, *443
 resistance, 122-124
 and sulfonylureas, *552
 and tolbutamide, S37
 Kimmelstiel-Wilson lesions and diabetes, 197-199
 light sensitivity dermatitis, *346
 lipodystrophic muscular hypertrophy, *77
 marrow aplasia, fatal, *353
 mitotic figures in islets of Langerhans, 36-37
 mumps parotitis, *549
 nephrotic-like syndrome, *443
 pancreatectomy and pre-existing diabetes, 118-119
 pancreatic islet cell adenoma, *72
 psychologic factors in diabetes control, *350
 renal
 glucosuria, *547
 papillary necrosis, *157, *246
 salicylate therapy, long-term, *344
 sprue, nontropical, 388-390
 steatorrhea, diabetic, 390-391
 therapeutic problems in diabetes, *248
 varicella in infancy, *443

CATARACTS
 dietary aspects, 377
 in Hiroshima survey, 539
 after hypophyseal stalk section, 468

CEREBROSPINAL FLUID, and insulin, *347, *550-551

CHILD
 camp programs, *74, *249, S75
 corn oil diet effect, *550
 diabetes onset in identical twins, 395
 dimethylbiguanide therapy, *73

galactosemia, *552
 glucose tolerance curve in normal, 395
 hypoglycemia, 396, 421
 insulin resistance, 122-124
 lipodystrophic muscular hypertrophy, *77
 liver glycogen disease, *550
 phenformin and placebo study, *153
 questionnaire on diabetes, *247
 tolbutamide response test, S135
 twins, incidence in, 393-395

CHLOROTHIAZIDE
 and diabetes aggravation, *75
 and serum lipids, effect on, *441

CHLORPROMAZINE, placental transfer, S94

CHLORPROPAMIDE, *153-154
 advantages, 94-95
 albumin bound, S19-22
 and alcohol reaction, 40-42
 and blood sugar, 92, 95, *348, S62-68
 fasting levels, *246
 carbohydrate metabolism, effect on, *151
 comparison with
 azepinamide, S143
 BH 135, *439
 tolazamide, 218
 tolbutamide, S67
 and diabetes
 insulin control, *251
 maturity onset, *551
 severity, S50-54
 subclinical, S127-129
 and diet, *160
 failures, *72, *249
 secondary, 93
 fatty acids, effect on, S62-68
 and fibrinolysis, *553
 and glucose release, hepatic, S16-17
 and glucose-6-phosphatase, *151
 and hypoglycemia, *552
 insulinogenic potency, *349, S11-12
 and leucine, 397-400
 and liver, 84, 93-94
 long-term therapy, 91-95, *252
 and marrow aplasia, *353
 and nitrogen balance, S50-53
 and perinatal mortality, S99
 and photosensitivity, *346
 toxicity, 93-94, *349
 and weight, 94

CHOLESTEROL
 after acetohexamide therapy, 88
 and atherosclerosis, 65, *77, 144
 azepinamide effect, S71
 and corn oil diet, *550
 after exercise, 111-112
 in Hiroshima survey, 539
 MER-29 effect, *440
 and nicotinic acid, 144
 in obese mice, 212
 after orotic acid, *76

CHOROID
 microaneurysm in capillaries, 9
 thickening of basement membranes, 17

CIRCULATION
 brachial and insulin, 282-283
 and free fatty acid extraction, *347
 and glucose balance, hepatic, *346
 insulin, *245
 after sulfonylureas, S2
 Issekutz method, 222
 through neuropathic bone lesion, *76
 pancreatic, insulin-like activity, 504
 peripheral, sulfonylureas effect, S44-48
 portacaval shunt and hepatic glucose, 270
 portal, insulin effect on, *73
 retinal
 after hypophyseal stalk section, 468
 vascular reactivity, *74
 splanchnic, *152, *155

CIRRHOSIS
 diabetes, association with, *151-152
 and galactosemia, *552
 and galactosuria, *553
 and glucose output, hepatic, 270
 nutritional, *152

CLARA BARTON BIRTHPLACE CAMPS, S75

CLINISTIX TEST, 49-51, *345

CLINITEST, copper reduction, 53-55, 92, 111

COMA, diabetic, *73
 and hypoglycemia, *548
 and insulin therapy, 24-25

CORTICOTROPIN
 and microaneurysms, retinal, 18
 and serum proteins, 105-108

CORTISOL
See also Hydrocortisone
 and glucose metabolism, *550
 transcortin-bound, *350

CORTISONE
 acetate after adrenalectomy, 484
 and blood sugar, 211
 and glomerulosclerosis in rabbits, 296
 glucose tolerance test
 in diagnosis, S132
 in prediabetics, 50-51, 334, *350
 and hepatic synthetase, *78
 histological effects, 402-410
 and hypercholesterolemia, *551
 and hypophosphatemia, 31-34
 and hypophysectomy, 474-475
 and insulin resistance, 32
 liver enzyme, effect on, *159
 and sulfate, urinary, *551

COTTUS QUADRICORNIS L., carbohydrate metabolism, *154-155

COTTUS SCORPIUS, pancreatic islet cell study, *247

CUSHING'S SYNDROME, *158, 326

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume 11 Supplement, 1-150

September-October, 361-460
 November-December, 461-562

D

DBI. *See* Phenethylbiguanide

DEHYDROGENASE activities, 96-99

2-DEOXYGLUCOSE, and muscle sugar transport, 171-177

2-DEOXYGLUCOSE 6-PHOSPHATE, *78, 171

DEXTROTEST METHOD, *158

DIABETES MELLITUS

See also specific sites

and abdominal surgery, *344

abnormal remissions, *350-351

and achylia, *344

acid-base balance, 361-363

and acromegaly, 124

and Addison's disease, *78, *158, *548

adrenal glands, *158

hypertrophy and hyperactivity, 326

age factor in, 46-47, 52, 55, 61-63, 66

and azepinamide response, S143

in Japan, 535

alloxan-induced, 18, *77, *78

adrenal glands, weight gain, 318-320

and cold exposure, *444

fatty acid metabolism, 222-223

oxidation, impaired, 386

and pancreatectomy in dogs, 118

and reproductive organs of rats, *249

salicylate, insulin, and chlorpropamide effect on rats, *151

and serum-protein levels in rabbits, 106-107

and tolbutamide, S106-111

tubular calcification and pyelonephritis, 403

and weight gain, 321

and wound healing, *250

amelioration, spontaneous, and tolbutamide, S106, S114

angiopathy, 489

and hypophysectomy, 474-479

anorexigenic therapy, *74

Armanni-Ebstein lesion, 296

and bacteremia, *347

basement membrane thickening, 9, 199

beta-cell activity, *76

and blood groups, 329

brittle disease, *73

and Crystalline Insulin, *345

leucine administration, 397-400

protein metabolism deficiency, *154

stable, change to, *347

carbohydrate tolerance test, 44-45

carboxypeptidase concentration, *75

and carcinoma of pancreas, 120

characteristics, 24-28

chelating agents, *442

childhood, *75

and beef-pork insulin resistance, 124

and camp programs, *74, *249, S75

celiac disease, 388

dimethylbiguanide therapy, *73

and I.Q. levels, *342

and insulin resistance, 122-124

management, *74, *75, *548

and phenformin, *153

questionnaire response, *247

and chlorothiazide, *75

and chlorpropamide therapy, 40, 91-95, *246, *251, S50-54, S127-129, *551

and cholelithiasis, *252, *444

ciliary process, 9

circulatory problems, *73

and cirrhosis, S86, *151-152

classification, *73

complications, *246

atherosclerosis, 422, 425

cranial nerve palsy, *348

diarrhea, *159

and gastric secretion, *344

neuropathy, *153, *352

oculovasculorenal, 472

postoperative in gallstones, *252

in pregnancy, 335

renal lesions, 291-294, 296-304

urogenital, *552

vascular, 470-471

and hypophysectomy, 473-478

congenital, *347

control

and adrenalectomy, 484-485

with desiccated pancreatic extract, 120

after hypophysectomy, 480-481

and insulin therapy, *344

in Japan, 536-537

and neuropathy, *153

and physical activity, 114

psychologic factors, *350

and salicylate therapy, *344

and tolbutamide, S74-79

definition, 335

detection

Drives, 47-48, 81, *156

in older individuals, *440

and tolbutamide, *350, S97-98, S132-135, S138

Diabetes Week, 80, 162, 258, 356

"diabetic" index, *442-443

diagnosis, *73

screening tests, 44-45

and tolerance test results, S132-135

diet, *74, *157

dulation

and acetohexamide therapy, 87-88

and adrenalectomy, 488

and albuminuria, S85

and azepinamide response, S143

and azotemia, S85

and estrogen excretion, 517

and hypophysectomy, 480-481

in Japan, 537-538

and neuropathy, *150-153

and retinopathy, *153

by sex and age, S57

and tolbutamide response, S37, S85

emotional factors, *553

experimental and human, *76

and gallstones, *252

gangrene, amputations below knee, *346

gestational, 227

and glucosuria, pre-existing, *547

glycoprotein metabolism, 2, 18-19

and growth hormone, 18-19

hydrocortisone effect, 177

haptoglobin types, 331-332

hematological studies, 18

and hemochromatosis, *251

and heredity, 19, 329-330, 393-395, S138

and homozygosity, 56-65

hormonal regulation of glucose, *153

hospital responsibility, *444

and hypertension, 44-48

and hyperthyroidism, *156-157

and hypophysectomy, 469-470, 470-472

incidence, 239-240

in Britain, 66-69

in East Pakistan, *346

in Japan, 44-48

Hiroshima, 533-542

after mumps, *549

in New England town, *252

after pregnancy, 419

by sex and age, 66-69, *440, 536

in South Africa, Durban, *343

in United States, 66-69, *347

infection resistance, *551

insulin

complex, utilization of, 265-266, S34

-resistant, *73, *348, S34, S35-40

juvenile, 182

glomerulosclerosis, diffuse, *440

and growth hormone production, 18, *77

and hypophyseal stalk section, 465-468

and hypophysectomy, 461-462, 463-464, 472

and insulin sensitivity, 285, 308

in Japan, 540

and nuclear enlargement in islets of Langerhans, 38

and phenformin therapy, *153

and phenmetrazine hydrochloride therapy, *74

ketosis, *157

lipotrophic, *77, *344

manifestations, early, S72

maternal

and carbon dioxide pressure, *347

and menarchial age, 288

and subcutaneous fat necrosis, *351

maturity onset

and acetohexamide, *551

and azepinamide, S142-145, S146

combined oral hypoglycemic therapy, *249

and tolbutamide, S70, *551

metahypophyseal, *547

mild, and tolbutamide, S123-126

and mitochondrial reactions, *343, *546

and mitosis in islands of Langerhans, 38

and mucormycosis, *155

and mucoviscidosis, *75

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260
July-August, 261-360
Volume 11 Supplement, 1-150

September-October, 361-460
November-December, 461-562

SUBJECT INDEX 1962

after myocardial infarction, *251
and myotonic dystrophy, *552
necrosis in feet, *76
and nephropathy, *152
and obesity, 46-47, 70, 109
acetohexamide therapy, 87, 89
diethylpropion therapy, *549
and insulin antagonist, 72
sex factor, *151
and pancreatic cystic fibrosis, *73
patient instruction, 132-137
and phenformin therapy, 283
and physical training, 109-117
and polyneuropathy, *549
in pregnancy, *152
and fetal loss, *72, 228
and tolbutamide
therapies, S97-98
transfer, S98-96
protein synthesis, effect on, 145, *154
pyruvate level in blood, 285
radiation effect in Hiroshima, 535
renal
glomerular crescents in lesions, 303-304
papillary necrosis, *157
research tools, use of, *439
retinal vessels
changes in rats, *156
increase in number, 9
and oxygen inhalation, *74
and seminal deficiency, *349
severity
and leucine incorporation, *348
and serum protein-bound iodine
level, 193
and sulfonylureas, S50-53
sex factor, 46, *151
in East Pakistan, *346
and Simmond's disease, 18
and socio-economic levels, 46-47
special vocabulary, 135-136
and sprue, nontropical, 388-391, 436-437
stable
insulin secretion, S66
and phenethylbiguanide, *551
statistics on, 66-69
and cirrhosis, *151
and steatorrhea, 388-391, 436-437,
*439
subclinical and chlorpropamide, S127-129
survey
in Birmingham, England, *440
in Halstead, England, *441
in Hiroshima, Japan, 533-542
syndrome, 200
teaching in medical schools, 43, 48
therapeutic problems, *248
and thiazide drugs, *251
thiol substances and diabetogens, *347
and trace metals, *248
treatment, *72, *77, *248, 336-338
check list, 117
chlorpropamide and insulin, *251
conservative and gangrene, *547
exercise, diet, and insulin, 109

in Japan, 536-537
medical and surgical, *73
with oral hypoglycemic agents, *see*
Supplement, *72, 88-88, 91-95, *153-154, *155-156,
*249, *553
of prediabetics, *252
with sulfonylureas, S80-84
and tuberculosis in Japan, 539
in twins, 393-395
untreated
and diarrhea, *159
insulin-like activity, *158, 179
and vas deferens calcification, *152
DIABETES WEEK, 80, 162, 258, 356, 455

DIARRHEA
and neuropathy, *252
nocturnal, *159

DIET
adenine supplement, *76
and atherosclerosis, *77, 221, 338
beta-glucuronidase dosage, 65
caloric intake, *74, 113-114, 336, *350
and islet tissue, *551
and physical fitness programs, 111
and tolbutamide, S124-125
and tolerance tests, S132
carbohydrate intake, *154
and hyperglycemia, 510
and cataracts, 377
and cholesterol level, 144
and cirrhosis, *152
corn oil, *550
for diabetic children, *75
and "diabeticity" index, *442-443
and glucose

-galactose, *246
and nitrogen values, S50-51
uptake, *246
and glucostatic theory, *444
ground fox breeder ration, S115-116
in Japan, 536
and mellituria, *246
polyunsaturated vegetable fat in, 339
in pregnancy, diabetic, *152
protein

high, 338
and hyperinsulinism, *75
low, *250
restriction effect, *74
saltless, 337-338
soft, S116
starvation, 336

and glycogenolysis, *353
and hexose phosphates, *76
and steroid lesions, 402-405
in sulfonylureas therapy, S82
phenformin, S90
tolbutamide, S77, S90, S94
synthetic and glucose tolerance, *443
unrestricted and chlorpropamide, *160

DIMETHYLDIGUANIDE, *73
See also Metformin

E

EAST PAKISTAN, MEDICAL RESEARCH CENTRE, diabetes incidence, *346

ELECTROPHORESIS

Durrum method, 272
in Hiroshima survey, 539-540
insulin
antagonist mobility, 308-309
-binding capacity of plasma, 165
complexes, dissociation of, 268
derivatives, *553
free and bound, S26-28
protein and enzyme peaks, 273
serum patterns, 105
sulfonylureas, S19-21

EMIOCYTOSIS, 510-511

ENGLAND

diabetes survey
in Birmingham, *440
in Halstead, *441

ENZYMES

acetate determination, *76
activity
in acinar tissue, S5
and incubation, 96-97
and cortisone, *159
and galactose metabolism, *157
galactosemia, *552
and glycogen storage disease, *75,
*441, *547, *550
insulin degradation, 271-278
and toxicity, *442

EPINEPHRINE

and adrenalectomy, *159
carbon dioxide liberation, *247
and cortisol, *550
and fatty acids, 223-224, *252
-mobilizing activities, *343
and glucagon
and hypoglycemia, neonatal, *444
and glucose, hepatic, *549
glycogenolysis, effect on, *158
hexose phosphates concentrations, *76
and hyperglycemia, *250
and hypoglycemia in children, *72
and insulin, 396, 421
antagonism, 225
sensitivity, *343-344
and lipolysis, *246
and methandienone, *550
in urine after adrenalectomy, *159

ERYTHROCYTES

antibodies
activity, 413
and heat labile factor, 188
glucose
metabolism, *548
transfer, *349, *350
glucose-6-phosphate, *553
dehydrogenase activity, *442
pentose phosphate pathway, *78

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260
July-August, 261-360
Volume II Supplement, 1-150

September-October, 361-460
November-December, 461-562

ESTROGENS

excretion during pregnancy, *351
production, 517
and retinopathy, *250

ETHANOL

See also Ethyl alcohol
and galactose
elimination, *553
metabolism, *157

ETHYL ALCOHOL

See also Ethanol
and chlorpropamide, sensitivity to, 40-42
and galactose metabolism, *157
and tolbutamide, *442

EYE

See also Choroid, Retina, Retinopathy, cataracts, 377
hemorrhages, 463
myotonic dystrophy effect, *552
optic nerve glioma, 127

F

FAMILIAL TENDENCY, *76

See also Genes, Heredity
data on diabetes, request for, 71
and diabetes onset prognosis, 63-64
and haptoglobin types, 331-332
in Hiroshima, Japan, 534-535
and hypertension, *251
and hyperthyroidism, *156-157
and hypoglycemia, 397
and leucine sensitivity, *344-345
and menarchial age, 288
mucoviscidosis, *75
pancreatic cystic fibrosis, *73, *343
and perinatal mortality, *76, *156
and prediabetes, *72, 334
and renal lesions, 199
and tolerance tests, S133-135
in young diabetics, S123, S126

FATS. *See* Lipids

FATTY ACIDS

in adrenal cortex, 319
esterification, *442
free, removal and mobilization, *548-549
after glucose and epinephrine, *252
hepatic uptake, 222-225
insulin response, 366
metabolism, S44
myocardial, *152
oxidation by heart muscle, *248
rat epididymal fat pad, release from, *343
removal, *347
from plasma, *347
and serum, anti-insulin, *553
sulfonylureas effect, S61-68

FETUS

abnormalities, *72, S98, S99, 514
age and weight, *72, *152

carbohydrate metabolism in liver, *248
insulin-degrading factors, 420
islets of Langerhans development, *157
loss, *72, 228
and acidosis, *346
and estrogens, 516
macrosomia, *444
weight and mortality, 321

FIBRINOLYSIN, and arterial thrombi, *250

FLORINEF. *See* 9-alpha-fluorohydrocortisone

FOLIN-MALMROS METHOD, S104

FOLIN-WU METHOD, 204-208

FRUCTOSE 1:6-DIPHOSPHATE, *76

FRUCTOSE 6-PHOSPHATE, *76, *78

G

GALACTOSE

and hypoglycemia, neonatal, *444
metabolism, *157
uptake and insulin, *155, 422-423

GALACTOSEMIA, *157

congenital, *159-160, *552

GASTRECTOMY, and circulatory collapse, *152

GASTRIC SECRETION

basal and post-histamine, *344
and glucagon, *73, *75
insulin response, *547

GASTROINTESTINAL TRACT

azepinamide effect, S144
and diarrhea, diabetic, *159
and phenformin tolerance, *153, *349

GENES

See also Familial tendency, Heredity
and galactosemia, *160, *552
homozygosity, 56
and hypothalamus function, 209
and menarchial age, 288-289
mucoviscidosis and diabetes, *75
recessive diabetes permissible, 56
in twins, identical, 393-395

GLOMERULI

nodular lesions and insulin, 314
steroid treatment, effect of, 405-409

GLOMERULONEPHRITIS, *246

and glomerular crescents, 303-304

GLOMERULOSCLEROSIS, 9, 47, 197-200

in alloxanized rabbits, 107
and crescent formations, 303
forms, 296-304, *440
renal biopsies, *549
steroid-induced, 405-410
and vascular lesions, 302-303

GLUCAGON

and capillary blood sugar, *153
and gastric secretion, *73, *75
and glucose, hepatic, *549
and glycogen, hepatic, *77-78, *248
and glycogen storage disease, *444
and hepatomegaly, *550
high specific activity preparation, *347
and histamine dosage, *73
and hyperglycemia, *158
in infants, *153

in hyperinsulinism therapy, *75

and hypoglycemia, neonatal, *444

and insulin sensitivity, *343-344

in insulinoma detection, *250

and methandienone, *550

after phenformin therapy, *72

production site, 373

GLUCOCORTICOIDS

and glycogen synthesis, hepatic, *77-78

metabolism, effect on, *158

and muscle insulin response, 175-177

GLUCOSAMINE 6-PHOSPHATE, *78

GLUCOSE

See also Blood sugar, Glycosuria, Hyperglycemia

and adrenal steroids, 31-34

in adrenalectomized rats, *159

-binding by insulin, *342

and blood insulin-like activity, *247

carbon dioxide conversion, 368

liberation, *247, 319

and erythrocyte membrane, *349-350

and fibrinolysis, *553

and free fatty acids, 224

gastrectomized patients, effect on, *152

and glutathione stability, *345

hormonal regulation of, *153, 171-177

and hyperglycemia, *250

and hyperinsulinism, *74

Increment Index, S127-129

and insulin

free and bound, 70

after phenformin, *72

insulinogenic potency, *349, S11-12

labeled

in islet tissue of *Cottus Quadriramus L.*, *154

in pineal gland of goats, *249

in mathematical model, *159

metabolism

in diabetic rats, *78

hexose monophosphate pathway, S2

in ketosis, bovine, *351

myocardial, *152

and portacaval shunts, *73

and sulfonylureas, 507

and methoxypropyl-sulfonyl-urea, S16-17

and muscle protein synthesis, 145

oxidation

in erythrocytes, *78

insulin, effect of, 386

and overactive thyroid, *342

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

Volume II Supplement, 1-150

September-October, 361-460

November-December, 461-562

SUBJECT INDEX 1962

phlorizin effect, *249
 phosphorylation, 31, *442
 production, 366-368
 radioactive, *153
 retention and insulin, 270
 from retroperitoneal fibrosarcoma, *353
 and salt retention, *441
 skin-surface test, *76
 and blood test, 49-51, 202-203
 in prediabetics, 50-51
 and urine test, 49-51
 splanchnic blood flow and oxygen consumption, *155
 tolerance tests, *245, 534
 adrenal steroids effect, 31-32
 chloropropamide effect, S62
 diabetic index, *442-443, S104-114
 in diagnosis, S132
 glucose oxidase paper method, *440, *441
 infants of diabetic mothers, *245
 long-term follow-up, *440
 and methandienone, *549
 after myocardial infarction, *251
 in old people, *154
 and pancreatic cancer, *246, *439
 physiologic significance, *548
 and prediabetes, 384
 in pregnant
 diabetics, *72, 227
 nondiabetics, *158
 reproducibility, *245
 in siblings of diabetics, 395
 after surgery on sphincter of Oddi, *248
 and thiazide drugs, *251
 tolbutamide effect, S62, S109-114, S123-126
 transfer
 across cell membrane, *548, *549
 temperature and pH effect, *349
 and transfer inhibitors, *349-350
 uptake
 in aortic tissue, after insulin, 422
 in epididymal adipose tissue, 101-103, 179, 187, *246, S138
 Fick Principle, 281
 and glyceride-glycerol synthesis, *246
 and lactose, *246
 in liver, after insulin, 366-368
 after L-leucine, *440
 by myocardium, *547
 after radiation, *151
 uridine diphosphate, *77-78
 utilization and cystamines, *548

GLUCOSE - 6 - PHOSPHATASE, *151, *442
 and glycogen storage disease, *441, *444, *547, *550
 liver, increase in diabetic, 365
 sulfonylureas effect, S8
 and tolbutamide, S116-120

GLUCOSE-6-PHOSPHATE, *76, *78, *553
 and refeeding, *159

GLUCOSE-6-PHOSPHATE DEHYDROGENASE, *78
 beta and acinar cells, activity in, 98-99
 and hemolytic anemia, *345
 in *Mulia* population (Netherlands New Guinea), *442

GLUTAMIC ACID, *249

GLUTATHIONE
 and acetyl-phenyl-hydrazine, *345
 oxidized, 272, *345
 reductase, and disulfide bonds, 272-278

GLUTATHIONE-INSULIN TRANSHYDROGENASE. See Transhydronase

GLYCOCORTICOIDS, and serum proteins, 105-108

GLYCOGEN
 beta cell, deposition in, 427-431
 and glucagon response, *158
 and glucose phosphorylation, *547
 hepatic synthesis, *77-78
 metabolism
 and endocrine regulation, *78
 in skin, *151
 and phenformin, 285
 storage disease, *75, *441, *547, *550

GLYCOGENOLYSIS, mathematical model, *159

GLYCOPROTEIN
 in basement membrane, 294
 level in plasma, 18-19

GLYCOSURIA
See also Blood sugar, Glucose, Hyperglycemia
 and chloramphenicol therapy, *345
 in diabetes detection, *156
 and exercise, *74
 Fehling's method test, 49-50
 and growth hormone, *346
 and hypertension, 47
 incidence
 in Birmingham, England, *440
 in Halstead, England, *441
 insulin
 resistance, 125
 after nicotinic acid, 144
 and phenformin, S51-54
 in pregnancy, 227
 under stress, 213
 and tolazamide, 216

GOITER
 hyperendemic and nervous system defects, *442
 toxicity and diabetes, *342

GOLDTHIOGLUCOSE, and massive obesity, 209-212

GOLGI APPARATUS
 endoplasmic reticulum, 427
 and microinvaginations, 380-382
 vesicle distention, 428-429

GROWTH HORMONE
 dog islets, effect on, 426-433
 and fatty acid mobilizing activities, *343
 and glucose transport, 174-177
 and hyperglycemia, *551
 and hypophysectomy, 461
 and lipid metabolism, *346
 and lipolysis, *246
 and plasma amino-acid level in alligator, *247
 and protein
 -bound carbohydrate elevation, 18-19
 synthesis, *249
 sensitivity, 212-213

H

HAGEDORN JENSEN METHOD, 31, 44, 202, 210, S138

HEART

See also Myocardium
 contractility and sugar permeability, *78
 glucose uptake, *547
 muscle
 fatty acid oxidation, *248

HEART DISEASE

arteriosclerotic
 and serum lipids, *252
 coronary, *151
 amyloclastic action of saliva, *351
 in Hiroshima survey, 538
 and serum lipids, *252

HEMOCHROMATOSIS
 among Bantu diabetics, *251
 in Hiroshima survey, 538

HEMORRHAGE

in glomeruli, steroid-treated, 408-409
 and hypophysectomy, 462, 469, 471
 in plexiform layers of retina, 14
 resorption after adrenalectomy, 487-488
 in retinopathy, 466, 473
 and hypophyseal stalk section, 467-468
 vitreous, 484-485

HEREDITY

See also Familial tendency, Genes and blood
 groups, 329-330
 vessel defects, 19
 and cystic fibrosis, S136
 of diabetes, 393-395
 and prediabetes, S138
 recessive gene, permissive, 56
 galactosemia, *159-160, *552
 glucose tolerance, pathologic, *352
 and leucine sensitivity, *344-345
 obesity and hyperglycemia, 212-213
 single genetic locus, 56-65

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume II Supplement, 1-150

September-October, 361-460
 November-December, 461-562

HEXOSE MONOPHOSPHATE SHUNT
in beta cells, 98-99
and glucose metabolism, 99

HEXOSSES, and overactive thyroid, *342

HORMONES

See also specific substances

adrenal, *343-344
and estrogen administration, 514
and free fatty acid metabolism, 222-226
and glucose
production, *153
uptake, *352
and hypophysectomy, 474-475
insulin antagonists, *443
mammotropic and somatotropic, *250
and metabolic changes, 424
and sulfate, urinary, *551
testicular fat, effect on, *158
therapy during pregnancy, *351

HYALINE MATERIAL

in arterioles, 9-11
necrotic changes in retina, *351
in renal blood vessels, 299-300

HYALINE MEMBRANE DISEASE, *249

HYDROCHLORIC ACID, secretion-reducing factor, *344

HYDROCORTISONE

and adrenalectomy, 486-489
and blood sugar, 174
and glucagon response, *248
and hyperglycemia, 31-34
and muscle insulin response, 175-177
and plasma amino-acid level in alligator, *247

HYDROGEN ION CONCENTRATION

analysis, end-group, 273-274
and glucose transfer, *349
glycogen synthesis, effect on, 367-368

HYPERCHOLESTEREMIA

and cortisone, *551
sulfonylureas effect, 569-72

HYPERGLYCEMIA

after alloxanization, 106-107
and beta cell release, 511-512
and 2, 2'-bipyridine, *441-442
and blood pressure rise, *348
and cortisone, *551
in diabetic mothers, *245
after epinephrine, *250
after exercise, 109
after glucagon, *73, *158
goldthioglucose-induced, 209-213
and growth hormone, *346, *551
treatment, 432-434
and hepatic glucose, *73
and hypertension, renal, 47
in infants, *153
Cushingoid appearance, 326
water content, 324
insulin production, free and bound, 70

maternal and fetal, 321
after myocardial infarction, *251
after nicotinic acid, 144
under stress, 213
and tolazamide, 216
and toxemia of pregnancy, 227

HYPERINSULINISM

and islet cell tumors, *75
and islets of Langerhans, *153, *248
and neuropsychiatric problems, *72-73
symptoms, *75

HYPERLIPEMIA

glomerular, 410
after physical training, 114-115
sulfonylureas effect, S69-72

HYPERTENSION

and basement membrane thickening, 9
in diabetes detection, 44-48
and hemodynamic lesions, 304
and proteinuria, 538

HYPERTHYROIDISM

and carbohydrate oxidation, *442
familial tendency, *156
and monosaccharide uptake, 423-424
and radio-iodine therapy, *342

HYPERTRIGLYCERIDEMIA, S57

HYPOGLYCEMIA

after acetohexamide therapy, 84-87
and adrenalectomy, 487
from adrenocortical insufficiency, 171
azepinamide effect, S144
and brain syndrome, *72-73
in children, 396, 421
insulin-induced, *72
and chlorpropamide, 93, *160
and leucine, 397-401
as conditioned reflex, *342
desoxyribonucleic acid, *350
and gastric secretion, *852
glucose

-oxidase method in emergency, *351
radioactive, *549
after hypophysectomy, 468, 481
and indole-3-acetic acid, *349
in infants, S136-137, *549
and varicella, *443
and insulin, *547
antibodies, 519-522
derivatives, *553
and intrathoracic mass, *439
after leucine, *250
and leukemia, *247-248
and methandienone, *549
neonatal, *444
and phenformin, *160, 282-285
and pituitary insufficiency, 492
and retroperitoneal tumor, *548
and spinal cord lesions in rats, *158-159

spontaneous, *248, 337, *353
after tolbutamide, *250, S29, 507
islet cells, effect on, S125
and leucine, *547
treatment, *344

HYPOGLYCIN A

testicular fat, effect on, *158

HYPOPHYSEAL STALK SECTION

See also Hypophysectomy
and angiopathy, diabetic, 474
and retinopathy, 465-468, 470, 491-494

HYPOPHYSECTOMY

and adrenal weight, 324
after adrenalectomy, 487-488
and amino acid incorporation, *249
and diabetes insipidus, 474-475
and gastric secretion, *344
and glucagon reaction in baboon, *158
and hyperglycemia, 322-324
and water retention, 324
and weight of rat offspring, 323
and hypoglycemia, *342
and hypopituitarism, 175-176
and insulin, *155, 262
and islet weight studies, S116-120
and oculovasculorenal sequelae, 472
patient selection, 463, 466, 471, 473
and retinopathy, 461-462, 463-464, 491-494
beneficial changes, 467, 469
transantral-sphenoidal, 479, 480
for vascular diseases, 470-471

HYPOTENSION, postural, *352

I

INDEX

diabetic, S104-114
Increment, S128

INDOLE-3-ACETIC ACID

hypoglycemic activity, *349
insulinogenic potency, S12

INFANTS

blood sugar levels, *444
congenital defects and sulfonylureas, S98, S99, S144
of diabetic mothers
blood sugar, *153
and carbon dioxide pressure, *347
early vs. late feeding, *249
insulin secretion, *245
mortality, *156, S99-100, *549
subcutaneous fat necrosis, *351
erythroblastotic, and enlarged nuclei
in islets of Langerhans, 36
galactosemia, *552
and hypoglycemia, fatal, *443
islet cell adenomas, S136
size and estrogen, 517
and tolbutamide
response test, S135
transfer, S94-96

INSULIN

and oleic acid, *549
acetohexamide effect, 89
and acid metabolism, *546

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260
July-August, 261-360
Volume II Supplement, 1-150

September-October, 361-460
November-December, 461-562

SUBJECT INDEX 1962

activity, 369, *442
 action-like, 179, *249
 and adrenal steroids, 31-34, 165-169, *352
 in fibrosarcoma, *353
 after tolbutamide, 58, 504-508
 after adrenalectomy, 484
 allergy, *348
 and amino acid uptake, *342
 antiserum, *77, *160
 neutralization, 414-418
 preparations, 412-413
 aortic wall, effect on, 422-425
 assays, 69-70, *77
 Berson and Yalow method, *157
 beta cells, 101-104
 bound and free, *245
 epididymal fat pad method, 101, 172, 179, 184-185, *245, 506
 manometric, *245
 standard curve analysis, 413-414
 beef-pork, 124-125
 -binding
 of globulin, albumin, fibrin, antithrombin, 309, 317
 in glomerulosclerosis, 308-317
 and blood pressure, *348, 396, 421
 and carbohydrate metabolism, *245
 in cerebrospinal fluid, *347, *550-551
 characteristics, *344, *345
 and chloropropamide, *251
 circulating
 carrier protein bound, 417
 immunological studies, *77
 -coated bentonite particles, 520
 phagocytosis, 522-523
 coma, 24-25
 and cortisol, *550
 and mouse mammary tissue, *250
 Crystalline, 101, 125, *245, 262, 265, 309, 319
 and brittle disease, *345
 and serum antibodies, *151
 tolbutamide effect, S1, S26-33
 Zinc and hypoglycemia, 23-24
 and cyclotolheptamide, S12
 depot, *74
 derivatives, *553
 vs. diet control, 336-337
 dosage
 and binding capacity, 528-530
 and brittle disease, *347
 and coronary atherosclerosis, *77
 after exercise, 109
 and phenethylbiguanide, *348
 and serum phosphorus level, 29-32
 small and large, comparison, 23-30
 and steroid therapy, 166-168
 and epinephrine
 antagonism, 225
 excretion, *159
 free and complex, 262-266
 and free fatty acids, 224
 and galactose uptake, *155, 423
 and gamma globulin excess, 107
 and gastric secretions, *75
 and glucose, S14
 distribution, *549
 after fasting, 281
 metabolism, 26-29
 output, 270
 after phenformin, *72
 transfer, *548
 uptake, *346, S14
 in adipose tissue, *352
 by myocardium, *547
 and glucose-6-phosphatase, *151
 and glycogen synthesis, *77-78
 in guinea pigs, 104
 and heat labile factor complexes, 188
 hexose phosphates, effect on, *76
 and hexoses incorporation, *78
 history, 495-503
 human
 and antisera from guinea pigs, *160
 preparation and purification, *151
 and hyperadrenocorticism, 171
 and hyperthyroidism, 124, *342
 and hypoglycemia, *444
 in hypophysectomized dogs, *342
 hypophosphatemic effect, *547
 immunization
 by Morse method, 527
 and tolbutamide, S28-29
 Lente types, *160, *349
 and leucine, *552
 and liver glycogen disease, *550
 and liver synthetase, *78
 and metformin, *345
 and methandienone, *550
 mitochondria, effect on, *343, *546
 in pancreatic beta cells, 103
 peptides, chemical synthesis, *441
 and phenethylbiguanide, *551
 and phlorizin, *550
 and phosphate bond production, *343
 and potassium, *442
 transfer in rat liver, *156
 Protamine Zinc
 absorption from subcutaneous tissue, *245
 lipid, effect on, *158
 and wound healing, *250
 and protein synthesis, 144-147, *154
 in prediabetes, 145
 radio-active, solubility of, 273-274
 release mechanism, 510-511
 reoxidation, 278
 and reproductive organs, *249
 requirement, *74
 and dimethylbiguanide, *73
 after hypophyseal stalk section, 465-468
 after hypophysectomy, 462, 471, 474, 480
 and hypothyroidism, *248
 and metabolism, S82-83
 and pancreatectomy, 119-120
 and phenformin, long-acting, *153
 and pituitary insufficiency, 492
 and prednisone, 125
 and tolazamide, 220
 resistance, *73, *76, *440, *442, *443
 in albumin fractions, *76
 circulating antibodies, *348
 in diabetic child, 122-125
 to glucagon excess, 209
 and ketoacidosis, 23, 80
 and other disease states, *343
 in pregnancy, 227
 and steroid therapy, 168
 and sulfonylureas, *552
 tissue and serum, S41
 response
 in acromegaly, 171
 after growth hormone, 176-177
 and tolbutamide therapy, S35-40
 and salicylate binding, *350
 secretion
 in children, S136-137
 into pancreatic venous blood, *349
 sensitivity, 282
 in children, *72
 and deoxycorticosterone acetate, *343-344
 after epinephrine, *247
 in serum
 free and protein-bound, 69
 species specificity, *443
 stimulation
 in phosphate medium, 368
 and sulfonylureas, S12
 storage form, 510
 and thiazide therapy, *251
 thyroxine degradation, correction of, 192
 and tolbutamide, *546
 comparison of effects, S26-33
 regulation by, S34-35
 tolerance
 after adrenal steroids, 31-32
 transhydrogenase reduction, 271-278
 withholding effects on liver, 366
 and xylose uptake, 422
 and zinc association, *248, *345, *349

INTERNATIONAL DIABETES FEDERATION
 Fifth Congress, 258, 356
 Fourth Congress
 erratum, 387
 papers presented, 138-143, 228-235

IODINE, serum protein bound, 193-195

ISCHEMIA
 neuropathy, *76
 vibratory perception changes, *350-351

ISLETS OF LANGERHANS
 amino acids distribution, *154-155
 cells
 alpha, elimination of, 97-98, 102-103
 beta
 degranulation, 212
 hyperplasia, S129
 and insulin, 509-513
 and dehydrogenase activity, 98-99
 fetal development, *157
 glucagon content
 staining techniques, 371-372
 glucose
 carbon incorporation, *249
 metabolism, *154-155

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume II Supplement, 1-150

September-October, 361-460
 November-December, 461-562

SUBJECT INDEX 1962

hyperplasia, *153, *248
in animals, 35, *74
insulin concentrations in, 102-103
microchemical studies, 96-100
mitotic figures, 37-38
nuclei, enlarged, 36
pregnancy effect, 420
tumors, *158

ISSEKUTZ METHOD, 222

J

JAPAN
incidence of diabetes, 44-48
in Hiroshima, 533-542

JOLLIFFE, Norman, 147-149

JOSLIN, Elliott Proctor, 242-244

JOSLIN CLINIC, *76, 287, S69, S74

K

KETOACIDOSIS

See also Acidosis, diabetic
and bicarbonate conversion, 29
and I-C-14-acetate, *157
and insulin, Lente types, *160
and phenformin therapy, *160
in tropical regions, *346

KETONE BODIES

blood levels, *157
physiological role, *75
production
and acetate, *157
and insulin, 29-30

KETONEMIA

after fasting, *547
and insulin
dosages, 29
hypoglycemia, *439

KETOSIS, *76

and acetate, *157
and cerebral damage, *74
and chlorpropamide therapy, 93
endocrine gland role, *439
and exudative cellular response, *551
fatalities, *73-74
and glomerulosclerosis, diffuse, *440
insulin-like activity, 179
in Japan, 541
and lipogenesis, *351
in pancreatectomized animals, *247
and plasma fatty acids, 223

KIDNEYS

blood vessels
infarction, 304-305
glomeruli
basement membrane thickening, 291-294
lesions in dogs, 150

glomerulosclerotic, *440, 486
and insulin-binding, 310-317
hypophysectomy effect, 470, 473, 477, 479
impairment and surgery risk, 492
insulin uptake, S39
lesions
fluorescent insulin staining, 375
steroid-induced, 403-410
papillary necrosis, *157, *246
pyelonephritis, chronic, 466
substrates metabolism, *550

KIMMELSTIEL-WILSON SYNDROME, 9, 47, *440
in animals, diabetic and nondiabetic, 107-108, 150
basement membrane thickening, 294
and diabetes mellitus syndrome, 197-200

L

LACTIC ACID
myocardial metabolism, *152
production, *249

LEUCINE
and chlorpropamide, 397-400
and hypoglycemia, *547, *552
liver incorporation, *348
sensitivity, *250
in children, S136-137
familial tendency, *344-345

LEUKOCYTES
abnormality in galactosemia, *160
and glycogen-storage disease, *75
metabolic defect, *159-160

LIPIDS
in adrenal cortex, 17, 319
beta-glucuronidase effect, 65
chlorothiazide effect, *441
and corn oil diet, *550
in cortisone preparations, 296
in diet, diabetic, *350
and glucose uptake, *246, 367
hormones, effect of, *158
metabolism, *74, S57
endocrine influences, S61-68
and hypophysectomy, 471
orotic acid effect on liver, *76
osmium tetroxide stain, 378
and peptide in urine, *246
pyruvate conversion, *248
in retinal
capillaries, 126
exudates, 12-14
and serum, anti-insulin, *553
tolerance, S56-60
transport and lipoprotein interconversions, *154

LIPODYSTROPHIC MUSCULAR HYPERTROPHY, *77

LIPOPROTEINS

and retinal and renal lesions, 107-108
ultracentrifuge study, *154

LIVER

amino acid incorporation, 145, *249
biochemical abnormalities, *441
and blood insulin-like activity, *247
chlorpropamide effect, 93-94
cirrhosis and diabetes, *151
enzyme
insulin-degrading, 272-278
synthesis, *159
extract principle, *443
free fatty acid uptake, 222-223
function tests
after tolbutamide, S77, S87
glucose

and insulin, 270, *346, 366-368, *549

load disposal, S14
mathematical model, *159
output and renal excretion, S45
and phlorizin, *249
uptake, *73

glucose-6-phosphatase activity, *151

glycogen

content, 87, *158, S17
depletion, *159, *342
disease, *441, *547, *550, *553
insulin uptake, *157, S39
ionic patterns, 363-364
lipids, *553
and carbohydrates, *250
lipogenic inhibitory mechanisms, *250
metabolism and insulin, 366
mitochondrial reactions, *343, *546
and mitotic figures, 35-38
orotic acid effect, *76
phosphogluconate oxidation pathway, *441

and phosphorylase activity, *75, *159
potassium content and insulin, *156

in pregnant diabetics, *248

salicylates administration effect, *77

sulfonylureas effect, 507

and tolbutamide, *349

toxicity studies, 93

and triglycerides, *345-346

M

MARION COUNTY GENERAL HOSPITAL, DIABETES CLINIC, 87

MARYLAND, UNIVERSITY OF, HOSPITAL, 23-30

MASSACHUSETTS GENERAL HOSPITAL

diabetes patients, care of, *444

MAYO CLINIC, *74-75

MELLITURIA, *246

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260
July-August, 261-360
Volume II Supplement, 1-150

September-October, 361-460
November-December, 461-562

SUBJECT INDEX 1962

METABOLISM

- acid, in rat adipose tissue, *546
- carbohydrate, *151
 - in aortic tissue, 422-425
 - carbon dioxide requirement, 367-369
 - endocrine influences, S61-68
 - and heart disease, *351
 - in infants, *153
 - insulin effect, *245
 - and thiazide therapy, *251
- ethanol
 - tolbutamide effect, *442
 - fatty acids, *74, 222
 - d-galactose, *157
 - glucagon and adrenalectomy, *248
 - glucose, *249
 - cortisol effect, *550
 - in diabetic rats, *78
 - Emden-Meyerhof pathway, *246, 365
 - and hexokinase level, *548
 - hexose monophosphate shunt, 99
 - and insulin, 99, *353
 - and ketosis, *351
 - and phenformin therapy, 282-286
 - in pregnancy, *158, 227
- glutamate, *159
- glycogen in skin, *151
- glycoprotein in diabetics, 18-19
- hypophysectomy effect, 470-472
- and insulin
 - free and complex, S34-35
 - L(+)-lactate, effect on, *353
- lipids, S57
 - endocrine influences, S61-68
 - mannose in diabetic rats, *78
 - myocardial, *152
 - otic acid effect, *76
 - oxidative phosphorylation, *343, *546
 - phosphate, *343
 - protein, *154
 - and salicylate injections, *77
 - of substrates in kidneys, *550
 - thyroxine, 192-195
 - and tolbutamide, oral and intravenous, S43-48

METAHEXAMIDE

- alpha globulin bound, S19-22
- Bratton and Marshall procedure analysis, S19
- equilibrium dialysis, S19
- insulinogenic potency, S12
- toxicity, 89, 94, 216

METFORMIN, *345

METHANDIENONE, and carbohydrate metabolism, *549, *550

MICROANEURYSMS

- See also* Blood vessels, Retinopathy in capillaries
 - extraretinal, 8-9
 - retinal, 4-14, 126-130
 - and mesodermal bridges, 17, 126-130
 - and pericyte degeneration, 8 sites, 4-11

- and corticotropin therapy, 18 and perianeurysmal exudates, 12
- retinal
 - and hypophysectomy, 487

MICROSCOPY

- electron
 - of adipose tissue, 380-385
 - beta cell
 - degranulation, 427-429, S3-4
 - insulin determination, 104, S1
 - cellular hyperactivity effects, S5
 - of islets of Langerhans, 509-513
 - of mitochondrial membranes, 382-383
 - muscle biopsies, *353
 - of renal glomeruli, 9
 - of renal lesions, 199, 291-294
 - of retinal tissue, 2-4, 126
 - of teleostean pancreatic islet tissue, *247
 - glomerulosclerosis, pathogenesis of, 308-317
 - light
 - beta cell degranulation, 427-429, S3
 - muscle biopsies, *353

MORTALITY

- and cholelithiasis surgery, *252
- and complications, diabetic, *346
- diet, low-protein, *250
- from hyaline membrane disease, *249
- ketosis, *73-74
- perinatal
 - improved management, *551
 - and insulin therapy, S99-100
 - and pregnancy, diabetic, *72, *76, *152, *156, 321-324, *444, *549
 - and sulfonylureas, S99-100
 - postoperative in retinopathy, 491-492
 - by race, sex, and age, 66

MUCORMYCOSIS, *155

MUCOVISCIDOSIS, *75

MUHLBERG, William, 340-341

MUSCLE

- fiber loss in retina, *156
- glucose
 - metabolism, 366
 - uptake
 - regulation, *76
 - and sulfonylureas, S45
 - heart, and carnitine action, *248
 - hexokinase inhibitor, *76
 - insulin
 - and adrenalectomy, 175
 - physiologic effect, *443
 - lipodystrophic hypertrophy, *77
 - sarcoplasmic nuclei increase in fibers, *353
 - striated
 - d-galactose entry, *550
 - fatty acids utilization, S66
 - sugar transport, 171-177

MYOCARDIUM

- glucose uptake, *547

- infarction and hyperglycemia, *251
- metabolism, *152
- and oleic acid, *549

N

NATAL INDIANS

- diabetes incidence, *343
- pregnancy, diabetic
 - and chlorpropamide therapy, S99-100
 - and tolbutamide therapy, S99-100

NECROSIS

- bone changes, *76
- fat, subcutaneous, *351
- renal papillary, *157, *246

NEPHROPATHY

- and glomerulosclerosis, diffuse, *440
- and hypophysectomy, 462, 471, 473, 481
- and immunologic process, 304-306
- in Japan, 538
- without manifest diabetes, 197-199
- steroid-induced, in rabbits, 402-410

NERVOUS SYSTEM

- galactosemia, *552
- relation to disease, 191, 215

NETHERLANDS NEW GUINEA, MULIA REGION, cretinoid, hypothyroid syndrome prevalence, *442

NEUROPATHY

- classification and therapy, *77
- and growth-onset diabetes, *152-153
- and hypophysectomy, 478
- and hypotension, postural, *352
- and ischemia, *76
- and procaine therapy, *444
- and sprue, nontropical, 391

NEW ENGLAND town, incidence of diabetes, *252

NEW YORK DIABETES ASSOCIATION CAMP, *74, *249

NOREPINEPHRINE

- fatty acids, hepatic uptake, 223-225
- and insulin, 396, 421
- measurement by Von Euler and Flooding method, *72

NUTRITION

- See also* Diet
- Argentine Congress on, 260
- and cirrhosis, *152
- in diabetes management, *74, *157

O

OBESITY

- and anorexigenic therapy, *74
- and corticotropin secretion, *74
- and diabetes incidence, 46-47, *156

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260

September-October, 361-460

July-August, 261-360

November-December, 461-562

Volume II Supplement, 1-150

SUBJECT INDEX 1962

and diethylpropion, *549
and glucose tolerance, pathologic, *352
goldthioglucose induced, 209-214
hereditary and induced, 212-213
and hyperglycemia, *551
and insulin antagonists, *352
low incidence in tropical diabetes, *346
and phenmetrazine hydrochloride, *74
and sex factor in diabetes, *151
and tolbutamide response, S37-38
and total fasting, intermittent, *547

OHIO STATE UNIVERSITY, study of retinopathy, 1-22

ORAL HYPOGLYCEMIC AGENTS
See Sulfonylureas, specific compounds

OXYGEN

consumption, *249
and carbohydrate intake, *250
glucose effect, *155
insulin effect, 422
and retinal vascular reactivity, *74

P

PANCREAS

and alloxan toxicity, *442
alpha cells
beta cell ratio, S118-119
glucagon source, 372
beta cells
degranulation
after acetohexamide, 84
after tolbutamide, S2, S105-106,
S118
and insulin
determination, 99, 104, S1-2
volume, S107-108, S118
carcinoma, tolbutamide test, *246
cystic fibrosis, *73, *343
in children, S136
and glucose, venous, 505-506
and hyperglycemia, *158, 325
infant blood glucose response, *245
insulin
after carbutamide perfusion, S81
free, secretion of, S34
after glucose perfusion, S81
and butylbiguanide, S82
-like activity
and tolbutamide, S1
output during pregnancy, 420
release and sulfonylureas, S12
secretion into venous blood, *349
islet cells
adenomas, *156, *250, *439, S40,
S136
and leucine administration, 397-
400
and neuropsychiatric problems,
*72
diet effect, *551
dissection, 97-98
enlargement in newborn, S100
histochemistry, S3-4
microchemical studies, 96-100
and sulfonylureas, S66, S81

tolbutamide effect, S115-120, S125
ultrastructure in rabbits, S3
islets of Langerhans
fluorescent insulin staining, 375-376
and insulin, free and bound, *443
tumors
corticotropin-secreting, *74
removal, *552

PANCREATECTOMY, *77

acetohexamide effect, 84-85
and brittle disease, 118
and chlorpropamide and leucine ad-
ministration, 397-398
and glucagon reaction in baboon, *158
and growth hormone, 426-433
and hyperglycemia, *247
and insulin requirement, 118
and liver mitochondria, *343, *546

PAPERCHROMATOGRAPHY

in mellituria detection, *246
radio technic, *249
radioactive metabolites, study of, *155

PEPTIDES

bonds, hydrolysis of, 273-274
in urine, *246

pH

See Hydrogen ion concentration

PHENETHYLBIGUANIDE, *153-154

See also Phenformin

PHENFORMIN

See also Phenethylbiguanide
as adjuvant oral therapy, *72
alphaphtholdiacetyl reagent, *248
in biologic fluids and tissues, *248
with chlorpropamide
or tolbutamide, *343
dosages, S90
in gastrointestinal side effect pre-
vention, *343
failures, *249, S88-89
excretion, S51-54
production, S16-17
hypoglycemic action of, *72
and insulin, *155-156
glucose threshold, 282-286
and nitrogen balance, S51-54
oxidative enzymes, effect on, *153
and placebo study, *153
side effects, S88-89
and stress, metabolic, S90
timed-disintegration capsules, *153,
*348
and ketoacidosis, *160
and stable diabetes, *551
with tolbutamide, S77
or chlorpropamide, *343

PHLORIZIN

and glucosuria, *249
and insulin, *550

PITUITARY

function
and hypophyseal stalk section, 465-
468

hormonal increase during pregnancy,
18
and hyperglycemic action of glucagon,
*158
and hypophysectomy, 461-462
insufficiency and retinopathy, 491-492
and insulin antagonists, *352
and yttrium implants, 482-483

PLACENTA

carbohydrate metabolism, *248
chlorpromazine and tolbutamide trans-
fer, S93-96
insulin-degrading factors, 420

PLASMA

amino acid level in alligator, *247
carbon dioxide combining power in
diabetic acidosis, 24-26
fatty acids, 222-225
removal, *347

glucose
after phlorizin, *249
uptake and albumin, *351-352

glycerides
and diet, 339
growth hormone effect, *346

glycoprotein levels, 18-19
inorganic phosphorus increase, 325

insulin, *157
activity, 504-506
-binding capacity, 166-168, 527-532
disappearance, S38
after hypophysectomy, 176
and insulin resistance, *73
-like activity, 181, 261-266
after L-leucine, *440
after tolbutamide, S138
transport, *443
iron levels, *251

POTASSIUM

and acidosis, diabetic, 24
and insulin, *245
liver content, *156, *245

PREDIABETES

definition, *73, 334, 335
and genetic diabetogenic influence,
335

glucose tolerance tests

cortisone, 50-51

steroid, *73

and homozgosity, 56

and insulin

antagonist, 70

-like activity in serum, *158

and menarchial age, 288-289

and mucoviscidosis, *75

in pregnancy, 227, *444

and tolbutamide transfer, S93-96

and toxemia, *72

and protein synthesis, 145

and thiazide therapy, *251

and tolbutamide response, S138

PREDNISOLONE

and blood sugar levels, 107-108
histological effects, 402-410

and insulin sensitivity, *343-344

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

September-October, 361-460
November-December, 461-562

Volume II Supplement, 1-150

PREDNISONE
histological effects, 402-410
and I-C-14-acetate, *157
and insulin
dosage, 166
requirement, 125, *348

PREGNANCY
in diabetics
and azepinamide, S144
and carbohydrate
metabolism in rats, *248
tolerance tests, *72, *152
and carbon dioxide pressure, *347
and estrogen excretion, 514-518
and hormonal imbalance, *152
and hypophysectomy, 471
management, *72, *152, *444, *551
and perinatal mortality, *72, *152, 321-324
and phenmetrazine hydrochloride
therapy, *74
and reproductive wastage, *346
and tolbutamide, S93-96, S97-98
diabetogenic effect, 419-420
glucose
tolerance, *158, 227-228
utilization, *158
and insulin metabolism, *344
and retinopathy, 18

PRETOLBUTAMIDE
See Serum tolbutamide

PROTEIN
binding
of hexosamine, 18
of sulfonylureas, S18-25
catabolism evaluation, *248
glucose carbon incorporation, *249
leucine incorporation, *348
loss through glomerular filter, 293

PYELONEPHRITIS, *549
and hypophyseal stalk section, 466

PYRUVATES
disposal by fetal liver, *248
glycogen, conversion to, 365-366
and intracellular block, *548
metabolism, *159, S44
tolerance after phenformin, 285

R

REED, John Alton, 438-439

RETINA
See also Retinopathy
basement membranes
and pericytes, 2-3
thickening, 9
blood vessels
dilatation in rats, *156
reactivity, *74
capillary mesodermal bridges, 127
cribriform plate section, 11-12
cystoid degeneration, 13
hemorrhages in layers, 14
microaneurysms, 375

S

SALICYLATES
binding, *350
and carbohydrate metabolism, *151

SERUM
and acetohexamide, 83
alkaline phosphatase and sulfonylureas, 220
anti-insulin
from animals, 519-520
and blood sugar, S26-33
and insulin, S29-30
and lipids, *553
and tolbutamide, S1, S26-33
beta lipoprotein level, 89
bicarbonate, 29
bilirubin level, *249
and cationic exchange resins, *245
cholesterol, 65
after acetohexamide therapy, 88
in controlled diabetics, S55
heat labile factor, 183-191
human
and hypoglycemia, 523-524
and sulfonylureas, bound, S21-22
insulin, *73
antagonists, 102, 124
dosages, effect of, 23, 29
after fasting, 265-266
-immune and tolbutamide, S29-30
-like activity, *158, 179, *247, *343
and glucose injection, *548
during pregnancy, 419-420
and tolbutamide, S1, 511-512
manometric assay, *245, 419
lipids
chlorothiazide effect, *441
after fasting, *252
in Hiroshima survey, 539
and insulin, S56
and nephropathy, 410
and tolbutamide, S56
and liver glycogen disease, *550
phenformin content, *248
phosphorus, 29-32
polysaccharide metabolism, 293
proteins
antibodies in gamma globulin, 124
bound insulin, *245, *442
bound iodine, 192-195
electrophoretic patterns, 105-107
glycocorticoids and corticotropin effects, 105-108
and sulfonylureas, bound, S18-22
types of, and diabetes, 33¹
salicylate ion, binding of,
sulfonylurea concentrations,
tolbutamide, S94-95
urinary gonadotrophin level ... pregnant diabetics, *152

SIDEROSIS, in the Bantu, *251

SIMMOND'S DISEASE, 18

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
March-April, 83-164

May-June, 165-260
July-August, 261-360
Volume 11 Supplement, 1-150

September-October, 361-460
November-December, 461-562

SKIN

allergies

- and insulin, 124
- and sulfonylureas, 92-93
- and tolbutamide, S78
- and azepinamide, S144, S146
- blood vessel alterations, *441
- glycogen metabolism, *151
- radiation effect, *151
- surface-glucose test, 49-51, *76, 202-203

SOMOCYI-NELSON METHOD, 24, 49-50, 53, 87, *154, *158, 204-208, 217, 222, 426, S37, S94, S116, S135

SOUTH AFRICA, DURBAN, diabetes incidence, *343

SPINCER TECHNIC, S19, S94

STEATORRHEA, diabetic, *252, 388-391, 436-437

and jejunal biopsy, *439, 503

STEROIDS

- and adrenalectomy and hypophysectomy, 489
- and carbohydrate metabolism, *549
- and glomerular changes, 405-407
- and hypophosphatemia, 31-34
- and insulin resistance, 125, 165-169, *352
- and mitotic figures, 35
- nephropathy, 402-410
- urinary assays, *548

STRESS

- and glycosuria, 213
- metabolic, and tolbutamide, S77, S90
- and protein-bound carbohydrates, 18
- and temporary diabetes, 334

SUGAR

See Blood Sugar, specific substances

SULFADIAZINE, insulinogenic potency, S12

SULFATHIAZOLE, S22

SULFONYLUREAS

See also specific compounds
age factor in pregnancy, S100

AH 6848 (methoxypropyl-sulfonylurea), S16-17

BH 135, *439

and claudication, intermittent, *553

derivatives, effect of, S66

and "diabeticity" index, *442-443

and facial flushing, 41

failures, S81-82

and glucose uptake, S45

hematopoietic system, effect on, *346

hepatic action, 507

and hypercholesterolemia, S69-72

and hyperlipemia, S69-72

hypoglycemic

and hepatic glucose release, S16-17

potencies, 220

tolazamide, 216-221

- and insulin
 - hepatic action elucidation, S14
 - release, *349, S2, S12, S66, S115
 - resistance, *151, *552
 - therapy, *248
- insulinogenic potencies, S11-12
- and islet cells, S118, S125
 - exhaustion, S81
 - growth, S83
- nonhypoglycemic
 - and hepatic glucose release, S16-17
 - pharmacology, comparative, *348, *552
 - in pregnancy, diabetic, S99-100
 - protein interactions
 - in different animal species, S18-24
 - and stable diabetes, *551
 - tolazamide, 216-220
 - in treatment, *72, *153-154, *155-156, 216-220
 - long-term, *252, S80-84
 - of maturity-onset diabetes, *249
 - of nonobese patients, 89
 - and severity of diabetes, S50-53
 - and tropical diabetes, *346

SURGERY

for cholelithiasis in diabetics, *252,

*444

complications in diabetics, *73

criteria in retinopathy, 491-492

for fibrous mesothelioma, *548

and gangrene, diabetic, *346, *547

hyperinsulinism, *74-75

for hyperplasia correction, *248

hypophysectomy

mortality, 461, 463, 469, 470, 473,

480

operative procedure, 474, 479

and orthostatic hypotension, 478

preoperative evaluation, 463, 466,

471, 473

and vascular complications, 462

and isolated limb perfusion, *250

management

and hyperinsulinism, *74-75

and physicochemical imbalance, *344

pre- and postoperative, *72

SWEAT, sodium and chloride concentration, *75

T

TEMPERATURE, and glucose transfer, *349

TES-TAPE TEST, 53-55, *345

TESTS

See specific tests

TETD. Tetraethylthiuram disulphide, 40-42

THIAZIDES, diabetogenic effect, *251

THROMBOSIS

and fibrinolysin, *250

retinal

in microaneurysms, 6-7

in small veins, 126

THYROID

function after hypophysectomy, 475

insulin stimulation of, 195

THYROXINE

metabolism and insulin, 192-195

and muscle glucose utilization, 176

TISSUE

acinar

enzyme activity, S5, 98-99

adipose

acid metabolism, *546

from alloxan-diabetic rats, *78

amino acid incorporation, 145

cortisol effect, *550

epinephrine effect, *247

from fasted and diabetic rats, 378-386

fatty acid composition, *549

and free fatty acids, 224-225, *347, *352

glucose

uptake, *76, 179, *246, *352

utilization, S64-66, *440

and insulin bound, *245

free and complex, 262-264

free, dissociation of, S34

physiologic effect, *443

response impairment, 177

sensitivity, *247

carbohydrate metabolism, *248, 422-425

hypoxia in infants, *351

islet

and caloric intake, *551

carbohydrate metabolism, *154-155

insulin assay, *245

volume and tolbutamide, S107

mouse mammary

and insulin and cortisol, *250

myocardial

glucose uptake, *547

peripheral

carbohydrate utilization and tolbutamide, S66

glucose threshold, 281-282, S44

pyruvate level, 285

phenformin content, *248

tumor, hypoglycemic factor, *350

TOLAZAMIDE

clinical evaluation, 216-220

and pregnancy, diabetic, S144-145

tolbutamide and chlorpropamide, comparison with, 218

TOLBUTAMIDE

*153-154, *349

and Addison's disease, *78

and adenosine triphosphatase, S8

albumin and pre-albumin fraction bound, S19-22

beta cells, effect on, S1, S2, S5, S105-106, S118, 510-511

and blood

lipids, S71

sugar, *348, *352, S62-68, S71

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82

March-April, 83-164

May-June, 165-260

July-August, 261-360

September-October, 361-460

November-December, 461-562

Volume II Supplement, 1-150

SUBJECT INDEX 1962

in body water, 89
 in cancer detection, *439
 in carcinoma diagnosis, *246
 in childhood diabetes, 125, S77
 comparison with azepinamide, S143
 chlorpropamide, S67
 insulin, S26-33
 tolazamide, 218
 dosages, 84, S77, S90
 and edema, nephrotic-like, *443
 ethanol metabolism, effect on, *442
 failures, *72, 92, 95, *344
 primary, S81, S88-89, S143
 secondary, S76, S81, S89, S143, *546
 fatty acids, effect on, S62-68
 and gastric secretion, *352
 and hepatic glucose release, S16-17
 and hepatitis, *349
 histochemical studies, S2-8
 hypoglycemia, *552
 and immune serum, S29-31
 and insulin
 degranulation and reduction, S46
 -immune rabbits, effect on, S28-29
 liberation, S5-6, S34
 regulation, S34-35
 resistance therapy, S35-41, *552
 secretion, 506-507
 insulinogenic potency, *343, *349, S11-12
 in insulinoma detection, *250
 and islet weight, S115-120
 and hypophysectomy, S119
 and leucine, *547
 long-term
 study, S74-79
 therapy, *252, S103-114
 and maturity-onset diabetes, S70, *551
 with metformin or insulin, *345
 in mild diabetes, S123-126
 and carbohydrate tolerance, S126
 and mouse viral hepatitis, *349
 and nitrogen balance, S50-53
 oral and intravenous
 and blood sugar, S46-47
 and metabolism, peripheral, effect on, S43-48
 pancreatic cancer test, *246
 with phenformin, *343, S77
 and prediabetes, *350
 and pregnancy, diabetic, S99-100
 detection, S97-98
 management, S97-98
 and renal toxicity, *443
 and severity of diabetes, S50-54
 side effects, S78
 and somatotropin, S118
 Spangler technic analysis, S19
 modification, S94
 testicular fat, effect on, *158
 thrombocytopenic effect, *346
 tolerance test
 in diagnosis, S132-135
 in infants and children, S135-137
 in prediabetes, S138
 toxicity, freedom from, S84-87
 ultramicroscopic studies, S2-8

TRANSHYDROGENASE, 271-278
 TRICHLOROACETIC ACID, end group analysis, 272-274

TRIGLYCERIDES

lipolysis, 225
 metabolism, S44
 in rat liver, *346

TRIIODOTHYRONINE

and glucose uptake, 423-424
 and ketonemia, *439

TRIPHOSPHOPYRIDINE NUCLEOTIDE, *78, 97-98, 275-278, *442
 and glucose-6-phosphate dehydrogenase deficiency, *345

TUMORS

beta cell and insulin release, 510
 corticotrophin-secreting, *74
 enzyme activity, S2
 glucose-uptake inhibitor, *353
 hypoglycemic factor, *350
 insulinomas and ulcerogenic, *552
 islet cell and peptic ulcer, *156
 kidney after steroids, 409-410
 retroperitoneal and hypoglycemia, *548

plasma amino acids, *247

in pregnancy
 estriol excretion, *351
 estrogen and pregnandiol, *152
 protein, 484, 538
 and hypophysectomy, 463, 477
 steroid assays, *548
 sugar content, *246
 and acetohexamide, 83
 and chloramphenicol, *345
 comparative test values, 53-55
 and cortisone, 211
 in detection survey, 44-45, *155, 534

after phenformin, *72
 and pituitary function, 492
 and tolbutamide, S104
 sulfonylureas excretion, 87
 sulfur, *551

URISTIX, 53-55

V

VASOPRESSIN, 277

VON EULER AND FLODING METHOD, *72

VON GIERKE'S DISEASE, enzyme defect, *441, *547

W

WEIGHT

and fetal loss, 321-323

gain
 after chlorpropamide therapy, 94
 and tolbutamide, *443
 in Increment Index, S128
 insulin assay, effect on, 414
 loss, *72, *250
 after adrenocorticosteroids, 107
 and phenmetrazine hydrochloride therapy, *74
 total fasting, intermittent, *547
 and triamcinolone, *443
 and sex, 536

WINNIPEG GENERAL HOSPITAL, *72

WORLD HEALTH ORGANIZATION resolution, 150-151

Y

YTTRIUM IMPLANTS

and pituitary destruction, 464
 for retinopathy, 482-483
 patient selection, 483

Z

ZINC, insulin association, *248

ZOLLINGER-ELLISON SYNDROME, *73

ZULUS, diabetes incidence, *343

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360

September-October, 361-460
 November-December, 461-562

Volume 11 Supplement, 1-150

AUTHOR INDEX 1962

In this index are the names of authors of articles that have appeared in *DIABETES* and those whose articles have been abstracted in the Journal during 1962. Entries marked with an asterisk (*) indicate authors of material that appeared in the *ABSTRACTS* only. Those preceded by the letter "S" refer to the Volume 11 Supplement entitled *Tolbutamide Therapy after Five Years*. The Subject Index appears on page 1.

A

Abboud, Francois M., *348
 Abelove, William A., 216-221, S142-146
 Abend, Melvin N., *343, *546
 Abt, Arthur F., *342
 Ack, Marvin, *342
 Acland, J. D., *245
 Adachi, Kenji, *151
 Adams, Levi C., *346
 Adams, Reuben H., *73
 Ainslie, D., 463-464
 Akedo, Hitoshi, *342
 Alexander, James D., 412-418
 Allen, Frederick M., 336-338
 Altman, Morris, *546-547
 Altmann, G., *342
 Altszuler, Norman, *153, *249
 Amatruda, Thomas T., Jr., *439
 Andersen, H. C., 474-479
 Anderson, George E., *72
 Anderson, Paul S., Jr., 533-543
 Anderson, R. C., 88-90
 Anderson, Robert S., *151
 Andres, Ruben, *245
 Andrews, Muriel M., *151
 Antoniades, Harry N., *245, 261-270, S34-35, S42
 Appels, Anton, 465-469
 Arab, M. M. H., S43-49
 Arbus, G. S., *549
 Arquilla, E. R., 183-191, *342-343, 412-418
 Ashe, Benjamin I., *153
 Ashmore, James, *159
 Ashton, Doris M., *441
 Auld, Peter A. M., *249
 Auld, W. H. R., *345
 Austen, K. Frank, *443

B

Back, N., *350
 Bahn, Robert C., *350
 Bailey, Donald W., *249
 Baird, Joyce D., *245
 Balash, W. R., 31-34, *547
 Ball, Eric G., *245
 Balodimos, Marios C., *245
 Baltzan, Marcel A., *245
 Banerjee, Gouri, *159
 Banfield, P. J., *348

Bank, H., *342
 Barden, Herbert, *442
 Barnes, P. H., *72
 Barrett, James C., *343, S35-41
 Barton, S. M., *342-343
 Bastenie, P. A., *548
 Bateman, J. R., 183-191
 Baum, John, 371-374
 Baxter, N., *349
 Bayrd, Edwin D., *350
 Beaser, Samuel B., S74, S103, S147
 Beck, John C., *343
 Becker, Bernard, 375-377
 Beigelman, Paul M., 179-182, 183-191, 261-270
 Belcher, Henry V., *548
 Bellens, R., *548
 Benbassat, J., *345
 Bencosme, Sergio A., 402-411
 Benedek, Thomas G., *251
 Benitz, K.-F., *158
 Bennett, Leslie L., *155
 Bentor, Victoria, 422-425
 Berkowitz, Donald, *246, *439, S56-61, S73, S141
 Bern, Howard A., *250
 Bernhart, F. W., *246
 Berns, A. W., 296-307, 308-317
 Berson, Solomon A., *151, *160
 Bessman, Samuel P., 23-30
 Best, Charles H., *439, 495-503
 Bewsher, P. D., *252, S127-130
 Beyer, Robert E., *343, *546
 Bianco, A. R., *348-349
 Bickel, Horst, *246
 Bingle, J. P., *439
 Bishop, Raymond H., Jr., *155
 Blackard, William G., *352
 Blahey, P. R., 514-518
 Blair, Alberta, *157
 Blanshard, Gerald, *76
 Blitz, Milton, *248
 Bloodworth, J. M. B., Jr., 1-22, *151-152
 Bloom, Arnold, *72
 Bloom, Walter L., *441
 Blumenthal, Herman T., 296-307, 308-317, S11, S26-33, S48
 Blumsohn, D., 202-203, S98-101
 Bonessi, J. V., *547
 Bookman, John J., S97-98
 Bortz, Walter, *246

Boshell, Buris R., *152, *158, *343, S35-41, S147
 Bothwell, T. H., *251
 Bougas, James A., 261-270, S34-35
 Bowers, C. Y., *246
 Brackenridge, R. G., S127-130
 Bradley, Robert F., S88-91
 Bradshaw, Marie, *442
 Brager, Stuart H., 23-30
 Brandstrup, Ebbe, *72, *152
 Breidahl, H. D., *343
 Bremer, J., *548
 Broberger, O., *72
 Bronstein, Seymour, *159
 Brooks, Frank P., *547
 Brown, Arnold L., Jr., 388-392
 Bruno, Michael S., *439
 Bruns, Paul D., *351
 Bryan, John B., *160, 472
 Buchan, D. J., *439
 Buckle, A. L. J., S43-49
 Buckle, Richard M., *343
 Burgess, L., *440
 Burgess, T. L., *440
 Burt, Richard L., 227-228, 419-421
 Butler, Frank K., *252
 Butterfield, W. J. H., *72, *72, 281-286, *548, S43-49

C

Cader, Gordon, *245
 Cady, Lee D., Jr., *351
 Cahill, George F., Jr., *78, *246, 318-320, *550, S130
 Camerini-Dávalos, Rafael A., *158, *546, S74-80, S92, S147
 Camiel, Mortimer R., *152
 Campbell, G. D., *343, S98-101
 Camperlengo, Henry A., *72-73
 Canaan, Samuel, 375-377
 Carlsten, A., *152
 Carpenter, Anna-Mary, S103-115
 Carr, James H., Jr., *343
 Carruthers, Bruce M., *546
 Castenfors, H., *152, *155
 Castrillon, A. M., *440
 Chalmers, T. M., *246
 Charles, Rene N., *73, *343
 Chase, Joan W., *439
 Chase, Tom P., 393-396

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume 11 Supplement, 1-150

September-October, 361-460
 November-December, 461-562

AUTHOR INDEX 1962

Cherry, Ruth B., *249
 Chiowanich, Pien, S135-137
 Chlouverakis, C., S43-49
 Chow, Donald C., *151
 Christensen, Halvor N., *342
 Clayton, H., *245
 Clifford, Nathan J., *343
 Clifford, Ruth C., *154
 Cogan, David G., *246-247, *252, *351
 Cohen, Alan S., 204-208
 Cohen, Nathaniel, *73
 Coleman, Stan L., 375-377
 Collens, William S., *546-547
 Collyer, Robert T., *152-153
 Colwell, Arthur R., Jr., 504-508
 Colwell, Arthur R., Sr., S13, S50-55, S55,
 S92, S101, S130, S147
 Combes, Burton, *73
 Conard, V., *548
 Conn, Jerome W., 335, S123-126
 Constat, Georg, 138-143, 228-235
 Cooke, J. N. C., *549, *549-550
 Cornblath, Marvin, *153
 Correa, P. Riet, *247
 Cotton, L. T., *553
 Coulson, Roland A., *247
 Coyle, Maurice J., *252
 Creutzfeldt, Werner, *343-344
 Cristofori, Fred C., *547
 Cunningham, Paul, *552

D

D'Amato, Elisa, *246
 Danforth, W. H., *547
 Danowski, Thaddeus S., *73, 239-240,
 *547
 Davidson, John K., S115-120
 Davis, Richard A., *547
 Davis, Thomas R. A., *444
 de Alvarez Buylla, Elena R., *342, *342
 de Alvarez Buylla, R., *342
 De Bodo, Richard C., *153
 De la Harpe, P. L., *73
 Deuticke, Ursula, *343-344
 Di George, Angelo M., S131, S135-137
 Ditschuniet, Hans, S12, S13, S42
 Ditturi, Bessie, *153
 Dobkin, Gerald B., *546-547
 Dobson, Harold L., *154, S102
 Dolger, Henry, S97-98, S101, S130, S146
 Dokart, Ralph E., 519-526
 Dominguez, J. M., 469-470
 Doray, B. H., *550
 Dotevall, Gerhard, *344, *344
 Drapkin, Arnold, *344
 Dreiling, David A., *73
 Drorbaugh, James E., *249
 Drose, Vera E., *351
 Drucker, William D., *547
 Duncan, Garfield G., *547

E

Eberlein, Walter R., *547
 Echenique, Raul, 216-221, S142-146
 Ecksteir, John W., *348

Egdahl, Richard H., *247
 Eisentraut, A. M., *347
 Ekengren, Kristina E. K., 109-117
 Eldjarn, L., *548
 Eliasch, H., *152
 Elkins, Carol M., *441
 Ellenberg, Max, 197-201
 Elliott, F. A., *353
 Engel, Frank L., *352, *439
 Engel, Lewis L., *548
 Enquist, Irving F., *250
 Etzwiler, Donnell D., *247, *548
 Ezrin, Calvin, *548

F

Fabrykant, Maximilian, *153
 Fajans, Stefan S., *73, 335, S49, S102,
 S122, S123-126, S130, S139
 Falkmer, Sture, *247
 Farquhar, James W., *73, *245
 Felbo, M., *76, *156
 Ferguson, Arthur W., *73
 Ficarra, Bernard J., *344
 Field, James B., *73, 165-170, *247,
 *440
 Field, Richard A., *346, *444, 465-469,
 S141
 Finch, Stuart C., *551
 Finlay, J. M., *252
 Fish, Gilbert D., Jr., *153, *248
 Fitch, Ray F., *547
 FitzGerald, M. G., 40-43, *73-74
 Fitzpatrick, Hugh F., *250
 Flanders, Eric, *342-343
 Fleissner, Sylvia, *552-553
 Flute, P. T., *553
 Fosbrooke, Audrey S., *550
 Fosnaugh, Robert P., *346
 Fowler, A. F., 514-518
 Francis, John O'S., 204-208
 Franckson, J. R. M., *548
 Frantz, Virginia K., *156
 Fraser, Robert I., *547
 Fraser, Russell, *77, 482-483
 Freedman, Louis, *248
 Freinkel, Norbert, *344
 Friedman, Gerald J., *74, *344
 Fritz, Irving B., *160, *248
 Fry, I. Kelsey, *72, *548
 Fugmann, Ulla, *76

G

Gaddie, R., 40-43
 Gajdusek, D. C., *442
 Ganzon, Angelita F., *153
 Garcia-Fernandez, M. C., *440
 Garfield, Claude R., *548
 Gaston, J. Harper, *547
 Gellman, Derek D., *440
 Gersing, Albert, *441
 Gertler, Menard M., *351
 Ghitman, Bernard, *441
 Gilat, T., *342
 Gilgore, Sheldon G., *344
 Gittler, Robert D., *248

Glasser, Elaine J., S18-25
 Glasser, Stanley R., *248
 Glassman, Sol, *246, *439
 Glick, Seymour M., *248
 Gold, Martin, *347, *548-549
 Goldberg, Harold, *247
 Goldman, Allen S., 122-125
 Goldner, Martin G., *154, *553
 Goldstein, Maurice S., *442
 Gomez, Ruben, 105-108
 Goodell, R. A., Jr., *344-345
 Goodman, Joseph I., *153-154
 Goodner, Charles J., *344
 Gordon, Edgar S., 470-472
 Gordon, Edwin E., *154
 Gordon, Harry H., *153, *549
 Gordon, Mordecai H., *153
 Gottfried, Sidney P., *154
 Gottlieb, B., *345
 Graef, Irving, 485-490
 Graig, Frank A., *248
 Granville, George E., *251, *350
 Green, Paul A., 388-392
 Greenac, E. R., *345
 Greenberg, E., 469-470
 Greenberg, Leonard, *246, *439
 Greenberg, Sigmund R., *441
 Griffin, A. Clark, *154
 Groen, J. J., *345
 Grundy, Scott M., *154
 Gumbel, W., *75
 Gundersen, Karen, *69-71, *245, 261-270
 Gunsberg, Ephraim, *248
 Gunson, H. H., 329-333
 Gunter, Laurie M., *151
 Gwinup, Grant, 397-401

H

Hadden, David R., 91-95
 Haft, David E., *74
 Hagerman, Dwain D., *248
 Hahn, Robert F., *444
 Haist, R. E., S115-120
 Hallgren, B., *152
 Halpern, Bernard, 519-526
 Handelsman, Milton B., *74, *441
 Hanley, T., S43-49
 Harding, P. G. R., 321-328
 Harkness, John, *441
 Harter, Melvin M., 118-121
 Hastings, A. Baird, 361-370
 Haunz, E. A., *248, *345
 Hausberger, F. X., *74
 Hazlett, Barbara E., *74, *152-153
 Hecht, Arthur, *154
 Heimann-Hollaender, E., *345
 Heimberg, Murray, *345-346
 Heller, H., *342
 Hellman, Bo, *154-155, *249, *551
 Hendon, James R., *441, *549
 Hernandez, Thomas, *247
 Herrera, M. Guillermo, *249
 Herring, Betty, *73
 Hetenyi, G., Jr., 236-239, *549
 Hickam, J. B., *74
 Higgins, F. E., *439

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume II Supplement, 1-150

September-October, 361-460
 November-December, 461-562

AUTHOR INDEX 1962

Hills, A. Gorman, 216-221, S61-68, S142-146
 Hinden, E., *549
 Hirata, Y., 44-48, 209-215, 298-307, 308-317, S26-33
 Hitselberger, James F., *346
 Hoagland, Robert J., *155
 Hoar, Carl S., Jr., *346
 Hobkirk, R., 514-518
 Hoffman, David L., *74-75
 Holding, Bruce F., Jr., *155
 Hollenberg, H. C., 378-387
 Hollis, William C., *75
 Holt, George W., *549
 Horino, M., 44-48, 209-215
 Hososako, A., 44-48, 209-215
 Houghton, B. J., *549-550
 Howell, Rodney R., *441
 Hoxtor, Gunther, *159
 Hubbell, John P., Jr., *249
 Hülsmann, W. C., *75
 Hultman, E., *152, *155
 Humbel, Rene E., *249
 Hunt, Ernest L., *249
 Hurwitz, David, *251
 Hurwitz, Gilbert E., 23-30
 Huston, C. J. W., *346

I

Ibrahim, Md., *346
 Ikkos, D., *159
 Illingworth, Barbara A., *547
 Isaacson, C., *251
 Isham, William H., *158, *248
 Ishimoto, M., 44-48, 209-215
 Ito, M., 44-48, 209-215
 Izzo, Joseph L., *248

J

Jackson, Robert L., *75, 393-396
 Jackson, W. P. U., 202-203, 334, S93, S98-101, S102, S138
 Jacobson, Marshall H., *549
 Jagenburg, R., *152
 Jakobsen, L. Kramer, *155
 Jakobson, Theodor, *346
 Janowitz, H. D., *73
 Javid, Manucher, 470-472
 Jensen, V. A., 474-479
 Jenson, William K., *547
 Johnson, Phyllis, *73
 Joplin, G. F., 482-483
 Joron, G. E., 514-518
 Jow, Eleanor, *75
 Juhl, Ole, *444

K

Káldor, Antal, S16-18
 Kantor, Nathan, 53-55, 204-208
 Kaplan, Eli, *248
 Kaplan, Norman M., S84-87, S102, S141
 Kark, Robert M., *440
 Kartchner, Max J., *351
 Katsoyannis, Panayotis G., *441

Katsuki, S., 209-215
 Katz, Isadore, *343
 Katz, Louis N., *77
 Katzen, Howard M., 271-280
 Kaye, Robert, 122-125
 Keeley, K. J., *251
 Keller, P., S138
 Kelley, Maurice L., Jr., *73, *343
 Kennan, Alfred L., *346
 Kennedy, A., *549
 Kenny, Alexander D., *441
 Kern, Lee R., *348, *551-552
 Kidson, C., *442
 Kiem, Iris, S61-68
 Kinch, R. A. H., 321-328
 Kinsell, Laurance W., 338-339, *346, 473-474
 Kipnis, David M., 171-178
 Kirtley, W. R., 83-90
 Kitzmiller, George E., *154
 Klausner, Howard, *345-346
 Kleiber, M., *351
 Kleiner, Israel S., *553
 Kline, Robert, *249
 Klotz, Roy G., *441
 Koch, E., *75
 Kokka, Norio, *155
 Kolodny, Edwin H., *249
 Korchak, Helen, *250
 Korn, C., *158-159
 Korner, A., *249
 Krahl, Maurice E., 144-146, *348
 Krall, Leo P., *252, S88-92
 Krebs, H. A., *75, *353
 Kreisberg, Robert A., 519-526
 Kuhl, W. James, Jr., 118-121
 Kuwabara, Toichiro, *246-247, *252, *351

L

Lacy, Paul E., 96-100, 101-104, 509-513, S1-2, S10
 Lancaster, Vance B., *155-156
 Landon, J., *549, *549-550
 Lanese, Richard R., 132-137
 Langman, M. J. S., *348
 Larsen, Jens A., *442
 Larsson, Stig, *154-155, *249
 Larsson, Yngve A. A., 109-117
 Law, Sam W., *251, *350
 Lazarow, Arnold, S10, S42, S103-115, S121
 Lazarus, Sydney S., *75-76, 426-435, *442, S2-10, S15, S122
 Leake, Norman H., 419-421
 Leboeuf, Bernard, *78, *550
 LeCompte, Philip M., 35-38
 Lee, James B., *550
 Lehmann, W., *75
 Lepow, Martha L., *443
 Levin, Ephraim Y., *158
 Levine, Rachmiel, *442
 Levitt, Leon M., *76
 Lilley, M. D., *351, *352
 Linder, Morton, *160, *249
 Lloyd, June K., *550

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360

Volume II Supplement, 1-150

September-October, 361-460
 November-December, 461-562

Lockie, G. N., *350
 Logue, Valentine, 463-464
 Lomax, Nancita R., *553
 Loosli, Edward S., 412-418
 Lotspeich, William D., *550
 Loughlin, Winifred C., *74, *249
 Lowe, Charles U., *550, *552-553
 Lowrie, William L., *160
 Lowy, Clara, *76
 Lozano-Castaneda, O., S74-80
 Lucas, C., *552
 Luft, Rolf, *159, 461-462
 Lukens, Francis D. W., 43, 48, S13, S15, S42, S49, S55, S74, S92, S103, S121, S148
 Lummis, Frederick R., Jr., *348, *551
 Lundbaek, Knud, *442-443, 474-479
 Lundquist, F., *76, *553

M

Macaulay, Alice I., *249
 Macdonald, I., *250
 MacDonald, Mary K., 291-295
 Madison, Leonard L., *73, 371-374, S13, S14-15, S49, S84-87
 Madsen, Joop, *442
 Magalhaes, E., *247
 Maha, G. E., 83-90
 Mahler, R. F., S15, S43-49
 Mahon, W. A., *347, *550-551
 Maier, Herbert C., 485-490
 Makino, N., 44-48, 209-215
 Malins, John M., 40-43, *73-74, 483-485
 Malmros, R., 474-479
 Mann, George V., *551
 Marble, Alexander, *158, *546, S74-80, S91, S101, S146, S148-150
 Markowitz, Alfred M., *156
 Marks, Bernard H., S61-68
 Marks, Herbert H., *347, 544-545
 Marks, Paul A., *78
 Marks, Vincent, *250
 Marrack, David, *250
 Martin, H. E., 183-191
 Martin, William J., *347
 Masoro, E. J., *250
 Massey, C. G., *353
 Matchar, Joseph C., *350
 Mazure, Pablo, *73
 Mazzacca, G., *348-349
 McCall, R. S., *347
 McCarron, Margaret M., *252
 McCormick, Donald B., *156
 McDermott, W. V., Jr., *346
 McElroy, William T., Jr., 222-226
 McGavack, Thomas H., *347
 McHenry, John I., *348, *551
 McHenry, Martin C., *347
 McKechnie, John K., *343, *347
 McKhann, G. M., *347, *550-551
 McKinsey, J. J., *547
 McKittrick, Leland S., *73
 Mehnert, Hellmut, S13, S74, S80-84, S92
 Meriwether, Thomas W., III, *353
 Merriam, Joseph C., Jr., 35-38
 Merrill, Margery A., *245
 Mertz, Walter, *443

Metz, Robert, 504-508
 Michaels, George D., *346
 Mikkelsen, William P., *252
 Miller, David I., S97-98
 Miller, Harvey I., *347, *548-549
 Miller, Irving, *342
 Mitchell, B., *245
 Mitchell, M. L., *347, *550-551
 Möller, Tage G. H. O., 109-117
 Molnar, George D., 527-532
 Montgomery, D. A. D., 91-95
 Moore, Michael J., *443
 Morey, Emily R., *441-442
 Morgan, Carl, S103-115
 Morrione, Thomas G., *441
 Morse, Jane H., *347
 Mortimer, Edward A., Jr., *443
 Mortimore, Glenn E., *156, *553
 Moses, Campbell, 31-34, *547
 Mosier, H. David, *153
 Mosovich, Luis L., *550, *552-553
 Muehrcke, Robert C., *440
 Muller-Ruchholz, W., S12
 Mulligan, Paula B., *443-444
 Munroe, John F., S69-73
 Murray, J. C., *553
 Musacchio, I. T. L., *156

N

Nabarro, J. D. N., 463-464
 Naide, Meyer, *76
 Nechemias, Charles, S97-98
 Nedelman, Philip B., *347-348
 Neely, Winston B., *348, *551
 Neu, Leo T., Jr., *252
 Neumann, Edith, *546-547
 Newcomb, Alvah L., *351
 Newman, William, *549
 Newholme, E. A., *76
 Nicholas, William C., *548
 Nicolopoulos, Demetrios, *153
 Nolan, James P., *551
 Norton, William S. II., *553
 Notelovitz, M., S98-101
 Nusimovich, Bernardo, S56, S103
 Nygaard, A., *76, *156

O

Ober, William B., *439
 Oei, T. L., *75
 Olen, Else, *552
 Oleson, J., *158
 Olsson, Ragnar, *247
 Ooms, H-A., *548
 Orht, V., 474-479
 Osler, Mogens, *72, *152
 Osserman, Kermit E., *156
 O'Sullivan, D. J., 40-43, *73-74
 O'Sullivan, John B., 53-55
 Overstreet, A. Evan, *250
 Owen, Charles A., Jr., 527-532
 Owen, John A., Jr., *551
 Owens, C. T., 296-307, 308-317
 Owens, John C., *348, *551-552

P

Palermo, N., *156
 Parker, Arthur M., 49-52
 Parker, Virgil J., *444
 Passmore, R., *76
 Paton, Donald M., *551
 Paul, Jerome T., *444
 Pawan, G. L. S., *246
 Pazianos, A., 469-470
 Pearson, O. H., 469-470
 Pedersen, Jørgen, *72, *76, *152, *156
 Peel, Sir John, *444
 Pegues, J. J., *353
 Pelz, Kurt S., *154
 Penhos, J. C., *348
 Pereda, Santiago A., *348
 Perillie, Pasquale E., *551
 Perkal, Stuart, S18-25
 Perkoff, Gerald T., *444
 Perlman, Lawrence V., *156-157
 Perrine, J., *158
 Petersson, Birger, *551
 Pettit, George, *246
 Pfeiffer, E. F., S12
 Phear, David, *76
 Pick, Ruth, *77
 Pickens, James M., 393-396
 Pieroni, Romulo R., *159
 Pirani, Conrad L., *440
 Poe, Robert H., *444
 Pogátsa, Gábor, S16-18
 Pokrajac, Niksa, *78
 Pollack, Herbert, 144, *156-157
 Pomeranz, Julius, *553
 Porter, Edith, *250
 Post, Richard H., 56-65, 287-290
 Pote, William W. H., Jr., S132-135
 Poucher, Russell L., S132-135
 Presley, Sophie J., *444
 Proper, George, *346
 Ptacek, Edward D., 412-418
 Pyle, Hugh M., 261-270, S34-35

Q

Quaade, Flemming, *444, *444

R

Rabkin, Mitchell T., *444
 Radding, Robert S., *348, *348, *551, *551-552
 Rajalakshmi, S., *76
 Rakow, Robert R., *546-547
 Randle, P. J., *76
 Ranke, Eugene J., *444
 Rasmussen, H., *76
 Rauda, Vija, *77-78
 Ray, B. S., 469-470
 R-Candela, J. L., *440
 R-Candela, R., *440
 Reaven, G., *552
 Recant, Lillian, S13, S139
 Redfern, Earl, *160
 Reid, William M., *250
 Reisler, David M., 171-178
 ReMine, William H., *74-75

Renold, Albert E., *78, *158, *249, *550
 Richards, J. G., *72
 Rick, W., *75
 Ricketts, Henry T., 150
 Riddick, Frank A., Jr., 171-178
 Ringler, I., *158
 Rivera, Evelyn M., *250
 Robb, Patricia, *157
 Roberts, H. J., *250
 Robinson, B. H. B., *348
 Robson, J. S., 291-295
 Rodriguez, R. R., *156
 Roediger, Paul, *441
 Rony, Hugo R., *157
 Root, Howard E., *77
 Root, M. A., 83-90
 Rose, F. Clifford, *250
 Rose, Herbert G., 192-196
 Rosen, David A., 402-411
 Rosen, Richard G., *250
 Rosenbaum, Louis, 375-377
 Ross, Alexander T., *348
 Rossano, P., *348
 Rothman, Stephen, *151
 Routledge, J. H., 514-518
 Rubin, Alan, *349
 Rubricius, Jeanette, *157-158
 Rudnick, Paul A., 533-543
 Rudolf, Arnold J., *249
 Rupp, Joseph J., *250, *344
 Ryder, Jill A., *157

S

Sabour, M. S., 291-295
 Sadow, H. S., *349
 Samaan, N., *77
 Samols, Ellis, *157
 Sandberg, A. A., *350
 Sarcione, Edward J., *550, *552-553
 Sarma, D. S. R., *76
 Sarma, P. S., *76
 Sato, T., 44-48
 Schein, Clarence J., *444
 Schepens, Charles L., 465-469
 Schmukler, Morton, 23-30
 Schnall, Charles, *76
 Schneierson, S. Stanley, *349
 Scholz, Donald A., *74-75
 Schwartz, Robert, *443-444
 Schwarz, Klaus, *443
 Sciales, William J., *352
 Seftel, H. C., *251
 Segal, Stanton, *157
 Segre, Eugene J., *552
 Segura, E. T., *342
 Selby, John B., *349
 Seltzer, Holbrooke S., *349, S11-12, S13, S73, S141
 Sen, A. K., *349, *349
 Senior, B., *77
 Sexton, Richard C., Jr., *350
 Shamoian, Charles A., *348, *546
 Shapiro, Alvin P., *251
 Shaw, Charles E., Jr., 28-30
 Sheldon, H., 378-387
 Shibolet, S., *342

DIABETES: VOLUME II PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360

September-October, 361-460
 November-December, 461-562

Volume II Supplement, 1-150

AUTHOR INDEX 1962

49, *550

Shipp, Joseph C., S13, S69-73, S74, S93, S130
 Shreeve, Walton W., *157
 Shuttleworth, John S., *548
 Sidbury, James B., *547
 Siegman, Felix, *547
 Sieker, H. O., *74
 Silagy, Joseph M., *552
 Silver, Abraham A., *350, *350
 Silverstein, Murray N., *350
 Silverstone, Felix A., *157-158
 Simon, Kenneth A., *552
 Simons, Bryan E., Jr., 371-374
 Simpson, Nancy E., 329-333
 Sines, Lloyd K., *548
 Singer, David L., *251
 Singleton, A. O., Jr., *552
 Sjögren, Björn, 479-481
 Skoryna, Stanley C., *75
 Slanetz, Charles A., Jr., *156
 Slater, J. D. H., *77
 Slaunwhite, W. R., Jr., *350
 Small, Jean L., *251
 Smetana, Hans F., *552
 Smith, Clement A., *249
 Smith, Kendrick, *77
 Smith, T. C., *158
 Smithies, O., 329-333
 Sokal, Joseph E., *550, *552-553
 Sokol, E. Marvin, *158
 Solomons, Edward, *157-158
 Soothill, John F., *440
 Sowton, Edgar, *251
 Spitzer, John J., 222-226, *347, *548-549
 Sprague, Randall G., 388-392, 436-437, 491-494, S41, S92, S121
 Stafford, Winifred L., *350
 Stamler, Jeremiah, *77
 Starin, Irving, *156
 Stauffer, J. Marvin, *251, *350
 Steiner, Donald F., *77-78
 Steiner, R. E., 482-483
 Steiness, Ib, *350-351, *351
 Steinke, Jürgen, *158, *347, *550-551, S43
 Sterky, Göran C. G., 109-117
 Stetten, DeWitt, Jr., 271-280
 Stevenson, J. A. F., 321-328
 Stewart, J. T., *547
 Stewart, Robert C., *251
 Stillman, Daphne, *77
 Stimson, William H., S146
 Stobo, E. A., *344-345
 Stowers, J. M., *252, S127-130
 Strickland, William, *73
 Striebel, James L., 527-532
 Strong, Jack B., Jr., *158
 Sube, John, *155
 Sullivan, James F., *252
 Sumi, S. M., *252
 Sutherland, James M., *347-348
 Suzuki, Kenui, *441
 Svanborg, A., *152

Sweet, William H., 465-469
 Szeinberg, Arieh, *78

T

Taft, H. Pincus, S56
 Tarrant, M. E., *553
 Taylor, E. Stewart, *351
 Taylor, Keith W., *249
 Teller, F. F., *349
 Thomas, Riley F., S74, S93
 Thompson, George, S93-97
 Thrush, Randolph S., 132-137
 Tietze, Frank, *553
 Timm, D. L., *347
 Tinsman, Clarence A., 239-240
 Tocci, Paul M., *157
 Tolstoi, Edward, *553
 Tomarelli, R. M., *246
 Tombropoulos, E. G., *351
 Tophøj, Else, *160
 Torres, José, *346
 Toussaint, Daniel, *246-247, *252, *351
 Traisman, Howard S., *351
 Tranquada, Robert E., 179-182, 183-191
 Treuting, Theodore F., *553
 Tsapogas, M. J., *553
 Tucker, Francis C., *153, *248
 Tunbridge, R. E., *439
 Turner, Naomi C., *351
 Turrill, Fred L., *252
 Tyberghein, Jean M., *158
 Tystrup, Niels, *553

U

Unger, Roger H., *347, 371-374, S15, S140
 Urbach, Stuart, *441, *549
 Urrutia, Guillermo, 318-320

V

Vallance-Owen, J., *351, *352
 Van Creveld, S., *75
 Van Gool, J., *158-159
 Vance, Vernon K., 318-320, *550
 Verner, John V., Jr., *352
 Villegas-Cinco, Aurora, *352
 Visintine, Robert E., *346
 Vlahos, Efstratios, *546-547
 Volk, Bruno W., *75-76, 426-435, S2-10, S101, S121, S130
 von Euler, U. S., *159
 Vranic, M., *78

W

Wagle, Shreepad R., *159
 Wahlberg, Fredrik, *352
 Wajchenberg, Bernardo L., *159

Wakim, Khalil G., *350
 Walcott, George, *159
 Walker, Geoffrey, *346
 Walker, Robert S., S56
 Watkins, M. L., *345-346
 Weaver, J. A., 91-95
 Weber, George, *159
 Webster, D. R., *75
 Wehrmacher, William H., *78
 Weil, William B., Jr., *342
 Weinberg, Arnold N., *159-160
 Weinstein, Ira, *345-346
 Weisenfeld, Shirley, *154
 Weiss, A., *352
 Weller, Charles, *160, *249
 Werkö, L., *152
 Wertheimer, H. Ernst, 422-425
 West, Kelly M., *160
 Wheeler, Anne H., *550
 Whichelow, M. J., *72, 281-286, S43-49
 White, Leslie L. R., *353
 Whitehouse, Fred W., *160
 Whitney, J. E., *353
 Widdas, W. F., *349, *349
 Wildberger, Henry L., S42, S92
 Wilkerson, Hugh L. C., 53-55, 204-208, *252

Wilks, Helen M., S50-55
 Will, L., *158
 Williams, Hibbard E., *247
 Williams, Robert H., *77-78, *245, S146
 Williamson, Joseph R., 101-104, *353, *353

Wilson, D. Laurence, 402-411
 Wilson, J. D., *440
 Winegrad, Albert I., 378-387, *546, S42, S121

Wishinsky, Henry, S18-25, S93-97, S147
 Wolff, O. H., *550
 Wollaeger, Eric E., 388-392
 Wolter, J. Reimer, 126-131
 Wood, Francis C., Jr., *78, S146, S147
 Wooten, Richard L., *353
 Wrenshall, G. A., 236-239
 Wright, David, S103-115
 Wright, Peter H., 519-526, *553
 Wyngaarden, James B., *441
 Wynn, Victor, *549, *549-550

Y

Yalow, Rosalyn S., *151, *160
 Yamauchi, M., 44-48
 Yue, Kenneth T. N., *160, *248

Z

Zachariah, P., *78
 Zacks, S. I., *353
 Zak, Sylvia, *248
 Zetterstrom, R., *72
 Zierler, Kenneth L., *245
 Zintel, Harold A., *250

DIABETES: VOLUME 11 PAGE NUMBERS BY ISSUE

January-February, 1-82
 March-April, 83-164

May-June, 165-260
 July-August, 261-360
 Volume 11 Supplement, 1-150

September-October, 361-460
 November-December, 461-562

Reviewers

The Editors of *DIABETES: The Journal of the American Diabetes Association* are grateful to the following persons who reviewed books during the year 1962; or who, although not members of the Editorial Board, evaluated scientific contributions to the Journal.

BOOKS

Deaconess Maude Behrman, Atlantic City
Harold Brandaleone, M.D., New York
James W. Craig, M.D., Cleveland
Martin G. Goldner, M.D., New York
Philip M. LeCompte, M.D., Boston
Alexander Marble, M.D., Boston
Jean Mayer, Ph.D., D.Sc., Boston
Peter E. Stokes, M.D., New York
Edward Tolstoi, M.D., New York
Robert C. Warner, M.D., New York
Gerald A. Wrenshall, Ph.D., Toronto

MANUSCRIPTS

James Ashmore, Ph.D., Indianapolis
Joseph T. Beardwood, Jr., M.D., Philadelphia
Bernard Becker, M.D., St. Louis
James Berkman, M.D., New Hyde Park, New York
Solomon A. Berson, M.D., New York
James M. B. Bloodworth, Jr., M.D., Madison
Oscar Bodansky, M.D., New York
Arthur R. Colwell, Jr., M.D., Wilmette, Illinois
Arthur R. Colwell, Sr., M.D., Chicago
Jerome W. Conn, M.D., Ann Arbor
Norman Deane, M.D., New York
Harold I. Farber, M.D., Reading, Pennsylvania
James B. Field, M.D., Bethesda, Maryland
Kenneth Zierler, M.D., Baltimore
W. Stanley Hartroft, M.D., Ph.D., Toronto
Paul E. Lacy, M.D., Ph.D., St. Louis
Leland S. McKittrick, M.D., Brookline, Mass.
Milton Mendlowitz, M.D., New York
Vaun A. Newill, M.D., Cleveland
Mary A. Root, Ph.D., Indianapolis
Harvey S. Sadow, Ph.D., New York
Holbrooke S. Seltzer, M.D., Dallas
Ethan A. H. Sims, M.D., Burlington, Vermont
Arthur G. Steinberg, Ph.D., Philadelphia
Priscilla White, M.D., Boston
Arne N. Wick, Ph.D., San Diego
Albert I. Winegrad, M.D., Philadelphia

